Gene therapy for hemophilia

Frontiers in Bioscience - Landmark

Volumn 20, Issue 3, 2015, Pages 556-603

  Rogers, Geoffrey L ^a   Herzog, Roland W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

AAV; Factor IX; Factor VIII; Gene therapy; Hemophilia; Lentivirus; Review

Indexed keywords

LENTIVIRUS;

GENE THERAPY; GENE VECTOR; HEMOPHILIA A; HEMOPHILIA B; HUMAN;

GENETIC THERAPY; GENETIC VECTORS; HEMOPHILIA A; HEMOPHILIA B; HUMANS;

EID: 84918781742     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4324     Document Type: Review

References (370)

1. M. J. Manco-Johnson, T. C. Abshire, A. D. Shapiro, B. Riske, M. R. Hacker, R. Kilcoyne, J. D. Ingram, M. L. Manco- Johnson, S. Funk, L. Jacobson, L. A. Valentino, W. K. Hoots, G. R. Buchanan, D. DiMichele, M. Recht, D. Brown, C. Leissinger, S. Bleak, A. Cohen, P. Mathew, A. Matsunaga, D. Medeiros, D. Nugent, G. A. Thomas, A. A. Thompson, K. McRedmond, J. M. Soucie, H. Austin and B. L. Evatt: Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med, 357(6), 535-44 (2007) DOI: 10.1056/NEJMoa067659
2. M. V. Ragni: The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders. Hematology Am Soc Hematol Educ Program, 2013, 44-51 (2013) DOI: 10.1182/asheducation-2013.1.44
3. O. Cao, B. E. Hoffman, B. Moghimi, S. Nayak, M. Cooper, S. Zhou, H. C. Ertl, K. A. High and R. W. Herzog: Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther, 17(10), 1733-42 (2009) DOI: 10.1038/mt.2009.159
4. D. M. Markusic, B. E. Hoffman, G. Q. Perrin, S. Nayak, X. Wang, P. A. Loduca, K. A. High and R. W. Herzog: Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol Med (2013)
5. M. Chitlur, I. Warrier, M. Rajpurkar and J. M. Lusher: Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia, 15(5), 1027-31 (2009) DOI: 10.1111/j.1365-2516.2009.02039.x
6. S. C. Gouw, H. M. van den Berg, J. Oldenburg, J. Astermark, P. G. de Groot, M. Margaglione, A. R. Thompson, W. van Heerde, J. Boekhorst, C. H. Miller, S. le Cessie and J. G. van der Bom: F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood, 119(12), 2922-34 (2012) DOI: 10.1182/blood-2011-09-379453
7. S. Halimeh, C. Bidlingmaier, C. Heller, S. Gutsche, S. Holzhauer, G. Kenet, K. Kurnik, D. Manner, A. Iorio and U. Nowak- Gottl: Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study. Biomed Res Int, 2013, 901975 (2013) DOI: 10.1155/2013/901975
8. G. Mariani, S. Siragusa and B. L. Kroner: Immune tolerance induction in hemophilia A: a review. Semin Thromb Hemost, 29(1), 69-76 (2003) DOI: 10.1055/s-2003-37941
9. C. R. Hay and D. M. DiMichele: The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood, 119(6), 1335-44 (2012) DOI: 10.1182/blood-2011-08-369132
10. D. M. Markusic and R. W. Herzog: Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia. J Genet Syndr Gene Ther, 1, 1-9 (2012)
11. K. H. High, A. Nathwani, T. Spencer and D. Lillicrap: Current status of haemophilia gene therapy. Haemophilia, 20 Suppl 4, 43-9 (2014) DOI: 10.1111/hae.12411
12. A. Gomez-Vargas and G. Hortelano: Nonviral gene therapy approaches to hemophilia. Semin Thromb Hemost, 30(2), 197-204 (2004) DOI: 10.1055/s-2004-825633
13. B. D. Brown, G. Sitia, A. Annoni, E. Hauben, L. S. Sergi, A. Zingale, M. G. Roncarolo, L. G. Guidotti and L. Naldini: In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood, 109(7), 2797-805 (2007)
14. J. Agudo, A. Ruzo, K. Kitur, R. Sachidanandam, J. M. Blander and B. D. Brown: A TLR and non-TLR mediated innate response to lentiviruses restricts hepatocyte entry and can be ameliorated by pharmacological blockade. Mol Ther, 20(12), 2257-67 (2012) DOI: 10.1038/mt.2012.150
15. F. Mingozzi and K. A. High: Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood, 122(1), 23-36 (2013) DOI: 10.1182/blood-2013-01-306647
16. C. H. Miao: Advances in Overcoming Immune Responses following Hemophilia Gene Therapy. J Genet Syndr Gene Ther, S1 (2011)
17. B. K. Sack, R. W. Herzog, C. Terhorst and D. M. Markusic: Development of gene transfer for induction of antigen-specific tolerance. Mol Ther Methods Clin Dev, 1 (2014)
18. F. Mingozzi and K. A. High: Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet, 12(5), 341-55 (2011) DOI: 10.1038/nrg2988
19. V. R. Arruda, J. N. Hagstrom, J. Deitch, T. Heiman-Patterson, R. M. Camire, K. Chu, P. A. Fields, R. W. Herzog, L. B. Couto, P. J. Larson and K. A. High: Posttranslational modifications of recombinant myotubesynthesized human factor IX. Blood, 97(1), 130-8 (2001) DOI: 10.1182/blood.V97.1.130
20. H. Nakai, S. R. Yant, T. A. Storm, S. Fuess, L. Meuse and M. A. Kay: Extrachromosomal recombinant adenoassociated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol, 75(15), 6969-76 (2001) DOI: 10.1128/JVI.75.15.6969-6976.2001
21. C. Kaeppel, S. G. Beattie, R. Fronza, R. van Logtenstein, F. Salmon, S. Schmidt, S. Wolf, A. Nowrouzi, H. Glimm, C. von Kalle, H. Petry, D. Gaudet and M. Schmidt: A largely random AAV integration profile after LPLD gene therapy. Nat Med, 19(7), 889-91 (2013) DOI: 10.1038/nm.3230
22. A. K. Zaiss, Q. Liu, G. P. Bowen, N. C. Wong, J. S. Bartlett and D. A. Muruve: Differential activation of innate immune responses by adenovirus and adenoassociated virus vectors. J Virol, 76(9), 4580-90 (2002) DOI: 10.1128/JVI.76.9.4580-4590.2002
23. A. K. Zaiss and D. A. Muruve: Immune responses to adeno-associated virus vectors. Curr Gene Ther, 5(3), 323-31 (2005) DOI: 10.2174/1566523054065039
24. Z. Wu, A. Asokan and R. J. Samulski: Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther, 14(3), 316-27 (2006) DOI: 10.1016/j.ymthe.2006.05.009
25. R. W. Herzog, J. N. Hagstrom, S. H. Kung, S. J. Tai, J. M. Wilson, K. J. Fisher and K. A. High: Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A, 94(11), 5804-9 (1997) DOI: 10.1073/pnas.94.11.5804
26. R. W. Herzog, E. Y. Yang, L. B. Couto, J. N. Hagstrom, D. Elwell, P. A. Fields, M. Burton, D. A. Bellinger, M. S. Read, K. M. Brinkhous, G. M. Podsakoff, T. C. Nichols, G. J. Kurtzman and K. A. High: Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med, 5(1), 56-63 (1999) DOI: 10.1038/4743
27. P. A. Fields, D. W. Kowalczyk, V. R. Arruda, E. Armstrong, M. L. McCleland, J. N. Hagstrom, K. J. Pasi, H. C. Ertl, R. W. Herzog and K. A. High: Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther, 1(3), 225-35 (2000) DOI: 10.1006/mthe.2000.0032
28. J. N. Hagstrom, L. B. Couto, C. Scallan, M. Burton, M. L. McCleland, P. A. Fields, V. R. Arruda, R. W. Herzog and K. A. High: Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter. Blood, 95(8), 2536-42 (2000)
29. M. A. Kay, C. S. Manno, M. V. Ragni, P. J. Larson, L. B. Couto, A. McClelland, B. Glader, A. J. Chew, S. J. Tai, R. W. Herzog, V. Arruda, F. Johnson, C. Scallan, E. Skarsgard, A. W. Flake and K. A. High: Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet, 24(3), 257-61 (2000) DOI: 10.1038/73464
30. C. S. Manno, A. J. Chew, S. Hutchison, P. J. Larson, R. W. Herzog, V. R. Arruda, S. J. Tai, M. V. Ragni, A. Thompson, M. Ozelo, L. B. Couto, D. G. Leonard, F. A. Johnson, A. McClelland, C. Scallan, E. Skarsgard, A. W. Flake, M. A. Kay, K. A. High and B. Glader: AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood, 101(8), 2963-72 (2003) DOI: 10.1182/blood-2002-10-3296
31. G. P. Gao, M. R. Alvira, L. Wang, R. Calcedo, J. Johnston and J. M. Wilson: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A, 99(18), 11854-9 (2002) DOI: 10.1073/pnas.182412299
32. T. R. Flotte, B. C. Trapnell, M. Humphries, B. Carey, R. Calcedo, F. Rouhani, M. Campbell-Thompson, A. T. Yachnis, R. A. Sandhaus, N. G. McElvaney, C. Mueller, L. M. Messina, J. M. Wilson, M. Brantly, D. R. Knop, G. J. Ye and J. D. Chulay: Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther, 22(10), 1239-47 (2011) DOI: 10.1089/hum.2011.053
33. C. Mueller, J. D. Chulay, B. C. Trapnell, M. Humphries, B. Carey, R. A. Sandhaus, N. G. McElvaney, L. Messina, Q. Tang, F. N. Rouhani, M. Campbell-Thompson, A. D. Fu, A. Yachnis, D. R. Knop, G. J. Ye, M. Brantly, R. Calcedo, S. Somanathan, L. P. Richman, R. H. Vonderheide, M. A. Hulme, T. M. Brusko, J. M. Wilson and T. R. Flotte: Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest, 123(12), 5310-8 (2013) DOI: 10.1172/JCI70314
34. J. R. Burnett and A. J. Hooper: Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. Curr Opin Mol Ther, 11(6), 681-91 (2009)
35. P. A. Fields, V. R. Arruda, E. Armstrong, K. Chu, F. Mingozzi, J. N. Hagstrom, R. W. Herzog and K. A. High: Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther, 4(3), 201-10 (2001) DOI: 10.1006/mthe.2001.0441
36. L. Wang, O. Cao, B. Swalm, E. Dobrzynski, F. Mingozzi and R. W. Herzog: Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther, 12(19), 1453-64 (2005) DOI: 10.1038/sj.gt.3302539
37. L. Wang, E. Dobrzynski, A. Schlachterman, O. Cao and R. W. Herzog: Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood, 105(11), 4226-34 (2005) DOI: 10.1182/blood-2004-03-0848
38. R. W. Herzog, P. A. Fields, V. R. Arruda, J. O. Brubaker, E. Armstrong, D. McClintock, D. A. Bellinger, L. B. Couto, T. C. Nichols and K. A. High: Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther, 13(11), 1281-91 (2002) DOI: 10.1089/104303402760128513
39. R. W. Herzog, J. D. Mount, V. R. Arruda, K. A. High and C. D. Lothrop, Jr.: Muscledirected gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther, 4(3), 192-200 (2001) DOI: 10.1006/mthe.2001.0442
40. G. Buchlis, G. M. Podsakoff, A. Radu, S. M. Hawk, A. W. Flake, F. Mingozzi and K. A. High: Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood, 119(13), 3038-41 (2012) DOI: 10.1182/blood-2011-09-382317
41. V. R. Arruda, H. H. Stedman, V. Haurigot, G. Buchlis, S. Baila, P. Favaro, Y. Chen, H. G. Franck, S. Zhou, J. F. Wright, L. B. Couto, H. Jiang, G. F. Pierce, D. A. Bellinger, F. Mingozzi, T. C. Nichols and K. A. High: Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood, 115(23), 4678-88 (2010) DOI: 10.1182/blood-2009-12-261156
42. J. D. Finn, T. C. Nichols, N. Svoronos, E. P. Merricks, D. A. Bellenger, S. Zhou, P. Simioni, K. A. High and V. R. Arruda: The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood, 120(23), 4521-3 (2012) DOI: 10.1182/blood-2012-06-440123
43. F. Mingozzi, Y. L. Liu, E. Dobrzynski, A. Kaufhold, J. H. Liu, Y. Wang, V. R. Arruda, K. A. High and R. W. Herzog: Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest, 111(9), 1347-56 (2003) DOI: 10.1172/JCI200316887
44. E. Dobrzynski, J. C. Fitzgerald, O. Cao, F. Mingozzi, L. Wang and R. W. Herzog: Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. Proc Natl Acad Sci U S A, 103(12), 4592-7 (2006) DOI: 10.1073/pnas.0508685103
45. O. Cao, E. Dobrzynski, L. Wang, S. Nayak, B. Mingle, C. Terhorst and R. W. Herzog: Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood, 110(4), 1132-40 (2007) DOI: 10.1182/blood-2007-02-073304
46. O. Cao, P. A. Loduca and R. W. Herzog: Role of regulatory T cells in tolerance to coagulation factors. J Thromb Haemost, 7 Suppl 1, 88-91 (2009) DOI: 10.1111/j.1538-7836.2009.03417.x
47. P. A. LoDuca, B. E. Hoffman and R. W. Herzog: Hepatic Gene Transfer as a Means of Tolerance Induction to Transgene Products. Current gene therapy, 9(2), 104-114 (2009) DOI: 10.2174/156652309787909490
48. M. Caridade, L. Graca and R. M. Ribeiro: Mechanisms Underlying CD4+ Treg Immune Regulation in the Adult: From Experiments to Models. Front Immunol, 4, 378 (2013) DOI: 10.3389/fimmu.2013.00378
49. A. T. Martino, S. Nayak, B. E. Hoffman, M. Cooper, G. Liao, D. M. Markusic, B. J. Byrne, C. Terhorst and R. W. Herzog: Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity. PLoS One, 4(8), e6376 (2009) DOI: 10.1371/journal.pone.0006376
50. B. E. Hoffman, A. T. Martino, B. K. Sack, O. Cao, G. Liao, C. Terhorst and R. W. Herzog: Nonredundant roles of IL-10 and TGF-beta in suppression of immune responses to hepatic AAV-factor IX gene transfer. Mol Ther, 19(7), 1263-72 (2011) DOI: 10.1038/mt.2011.33
51. B. M. Reipert, P. Allacher, C. Hausl, A. G. Pordes, R. U. Ahmad, I. Lang, J. Ilas, J. Windyga, A. Klukowska, E. M. Muchitsch and H. P. Schwarz: Modulation of factor VIII-specific memory B cells. Haemophilia, 16(102), 25-34 (2010) DOI: 10.1111/j.1365-2516.2008.01962.x
52. C. S. Manno, G. F. Pierce, V. R. Arruda, B. Glader, M. Ragni, J. J. Rasko, M. C. Ozelo, K. Hoots, P. Blatt, B. Konkle, M. Dake, R. Kaye, M. Razavi, A. Zajko, J. Zehnder, P. K. Rustagi, H. Nakai, A. Chew, D. Leonard, J. F. Wright, R. R. Lessard, J. M. Sommer, M. Tigges, D. Sabatino, A. Luk, H. Jiang, F. Mingozzi, L. Couto, H. C. Ertl, K. A. High and M. A. Kay: Successful transduction of liver in hemophilia by AAVFactor IX and limitations imposed by the host immune response. Nat Med, 12(3), 342-7 (2006) DOI: 10.1038/nm1358
53. A. C. Nathwani, E. G. Tuddenham, S. Rangarajan, C. Rosales, J. McIntosh, D. C. Linch, P. Chowdary, A. Riddell, A. J. Pie, C. Harrington, J. O'Beirne, K. Smith, J. Pasi, B. Glader, P. Rustagi, C. Y. Ng, M. A. Kay, J. Zhou, Y. Spence, C. L. Morton, J. Allay, J. Coleman, S. Sleep, J. M. Cunningham, D. Srivastava, E. Basner- Tschakarjan, F. Mingozzi, K. A. High, J. T. Gray, U. M. Reiss, A. W. Nienhuis and A. M. Davidoff: Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med, 365(25), 2357-65 (2011) DOI: 10.1056/NEJMoa1108046
54. R. W. Herzog: Immune responses to AAV capsid: are mice not humans after all? Mol Ther, 15(4), 649-50 (2007) DOI: 10.1038/sj.mt.6300123
55. F. Mingozzi and K. A. High: Immune responses to AAV in clinical trials. Curr Gene Ther, 7(5), 316-24 (2007) DOI: 10.2174/156652307782151425
56. F. Mingozzi, M. V. Maus, D. J. Hui, D. E. Sabatino, S. L. Murphy, J. E. Rasko, M. V. Ragni, C. S. Manno, J. Sommer, H. Jiang, G. F. Pierce, H. C. Ertl and K. A. High: CD8(+) T-cell responses to adenoassociated virus capsid in humans. Nat Med, 13(4), 419-22 (2007) DOI: 10.1038/nm1549
57. M. Cooper, S. Nayak, B. E. Hoffman, C. Terhorst, O. Cao and R. W. Herzog: Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Hum Gene Ther, 20(7), 767-76 (2009) DOI: 10.1089/hum.2008.161
58. R. Calcedo, L. H. Vandenberghe, G. Gao, J. Lin and J. M. Wilson: Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis, 199(3), 381-90 (2009) DOI: 10.1086/595830
59. S. Boutin, V. Monteilhet, P. Veron, C. Leborgne, O. Benveniste, M. F. Montus and C. Masurier: Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther, 21(6), 704-12 (2010) DOI: 10.1089/hum.2009.182
60. D. M. McCarty, P. E. Monahan and R. J. Samulski: Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther, 8(16), 1248-54 (2001) DOI: 10.1038/sj.gt.3301514
61. F. K. Ferrari, T. Samulski, T. Shenk and R. J. Samulski: Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol, 70(5), 3227-34 (1996)
62. D. M. McCarty, H. Fu, P. E. Monahan, C. E. Toulson, P. Naik and R. J. Samulski: Adeno-associated virus terminal repeat (TR) mutant generates selfcomplementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther, 10(26), 2112-8 (2003) DOI: 10.1038/sj.gt.3302134
63. Z. Wu, J. Sun, T. Zhang, C. Yin, F. Yin, T. Van Dyke, R. J. Samulski and P. E. Monahan: Optimization of selfcomplementary AAV vectors for liverdirected expression results in sustained correction of hemophilia B at low vector dose. Mol Ther, 16(2), 280-9 (2008) DOI: 10.1038/sj.mt.6300355
64. A. C. Nathwani, C. Rosales, J. McIntosh, G. Rastegarlari, D. Nathwani, D. Raj, S. Nawathe, S. N. Waddington, R. Bronson, S. Jackson, R. E. Donahue, K. A. High, F. Mingozzi, C. Y. Ng, J. Zhou, Y. Spence, M. B. McCarville, M. Valentine, J. Allay, J. Coleman, S. Sleep, J. T. Gray, A. W. Nienhuis and A. M. Davidoff: Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther, 19(5), 876-85 (2011) DOI: 10.1038/mt.2010.274
65. D. Raj, A. M. Davidoff and A. C. Nathwani: Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges. Expert Rev Hematol, 4(5), 539-49 (2011) DOI: 10.1586/ehm.11.48
66. J. Zhu, X. Huang and Y. Yang: The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest, 119(8), 2388-98 (2009) DOI: 10.1172/JCI37607
67. A. T. Martino, M. Suzuki, D. M. Markusic, I. Zolotukhin, R. C. Ryals, B. Moghimi, H. C. Ertl, D. A. Muruve, B. Lee and R. W. Herzog: The genome of selfcomplementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood, 117(24), 6459-68 (2011) DOI: 10.1182/blood-2010-10-314518
68. T. Wu, K. Topfer, S. W. Lin, H. Li, A. Bian, X. Y. Zhou, K. A. High and H. C. Ertl: Selfcomplementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome. Mol Ther, 20(3), 572-9 (2012) DOI: 10.1038/mt.2011.280
69. G. L. Rogers, A. T. Martino, G. V. Aslanidi, G. R. Jayandharan, A. Srivastava and R. W. Herzog: Innate Immune Responses to AAV Vectors. Front Microbiol, 2, 194 (2011)
70. S. M. Faust, P. Bell, B. J. Cutler, S. N. Ashley, Y. Zhu, J. E. Rabinowitz and J. M. Wilson: CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Invest, 123(7), 2994-3001 (2013) DOI: 10.1172/JCI68205
71. G. L. Rogers, A. T. Martino, I. Zolotukhin, H. C. Ertl and R. W. Herzog: Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. J Transl Med, 12(1), 25 (2014) DOI: 10.1186/1479-5876-12-25
72. M. Suzuki, T. K. Bertin, G. L. Rogers, R. G. Cela, I. Zolotukhin, D. J. Palmer, P. Ng, R. W. Herzog and B. Lee: Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo. Mol Ther, 21(4), 796-805 (2013) DOI: 10.1038/mt.2012.277
73. G. R. Jayandharan, G. Aslanidi, A. T. Martino, S. C. Jahn, G. Q. Perrin, R. W. Herzog and A. Srivastava: Activation of the NF-kappaB pathway by adenoassociated virus (AAV) vectors and its implications in immune response and gene therapy. Proc Natl Acad Sci U S A, 108(9), 3743-8 (2011) DOI: 10.1073/pnas.1012753108
74. L. Zhong, W. Zhao, J. Wu, B. Li, S. Zolotukhin, L. Govindasamy, M. Agbandje- McKenna and A. Srivastava: A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther, 15(7), 1323-30 (2007) DOI: 10.1038/sj.mt.6300170
75. L. Zhong, B. Li, G. Jayandharan, C. S. Mah, L. Govindasamy, M. Agbandje- McKenna, R. W. Herzog, K. A. Weigel- Van Aken, J. A. Hobbs, S. Zolotukhin, N. Muzyczka and A. Srivastava: Tyrosinephosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology, 381(2), 194-202 (2008) DOI: 10.1016/j.virol.2008.08.027
76. C. Li, Y. He, S. Nicolson, M. Hirsch, M. S. Weinberg, P. Zhang, T. Kafri and R. J. Samulski: Adeno-associated virus capsid antigen presentation is dependent on endosomal escape. J Clin Invest, 123(3), 1390-401 (2013) DOI: 10.1172/JCI66611
77. L. Zhong, B. Li, C. S. Mah, L. Govindasamy, M. Agbandje-McKenna, M. Cooper, R. W. Herzog, I. Zolotukhin, K. H. Warrington, Jr., K. A. Weigel-Van Aken, J. A. Hobbs, S. Zolotukhin, N. Muzyczka and A. Srivastava: Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to highefficiency transduction at lower doses. Proc Natl Acad Sci U S A, 105(22), 7827-32 (2008) DOI: 10.1073/pnas.0802866105
78. D. M. Markusic, R. W. Herzog, G. V. Aslanidi, B. E. Hoffman, B. Li, M. Li, G. R. Jayandharan, C. Ling, I. Zolotukhin, W. Ma, S. Zolotukhin, A. Srivastava and L. Zhong: High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surfaceexposed tyrosines. Mol Ther, 18(12), 2048-56 (2010) DOI: 10.1038/mt.2010.172
79. A. T. Martino, E. Basner-Tschakarjan, D. M. Markusic, J. D. Finn, C. Hinderer, S. Zhou, D. A. Ostrov, A. Srivastava, H. C. Ertl, C. Terhorst, K. A. High, F. Mingozzi and R. W. Herzog: Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood (2013) DOI: 10.1182/blood-2012-10-460733
80. T. L. Wu, H. Li, S. M. Faust, E. Chi, S. Zhou, F. Wright, K. A. High and H. C. Ertl: CD8(+) T Cell Recognition of Epitopes Within the Capsid of Adeno-associated Virus 8-based Gene Transfer Vectors Depends on Vectors' Genome. Mol Ther, 22(1), 42-51 (2014) DOI: 10.1038/mt.2013.218
81. E. Masat, G. Pavani and F. Mingozzi: Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. Discov Med, 15(85), 379-89 (2013)
82. C. D. Scallan, H. Jiang, T. Liu, S. Patarroyo-White, J. M. Sommer, S. Zhou, L. B. Couto and G. F. Pierce: Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood, 107(5), 1810-7 (2006) DOI: 10.1182/blood-2005-08-3229
83. H. Jiang, L. B. Couto, S. Patarroyo- White, T. Liu, D. Nagy, J. A. Vargas, S. Zhou, C. D. Scallan, J. Sommer, S. Vijay, F. Mingozzi, K. A. High and G. F. Pierce: Effects of transient immunosuppression on adenoassociated, virus-mediated, liverdirected gene transfer in rhesus macaques and implications for human gene therapy. Blood, 108(10), 3321-8 (2006) DOI: 10.1182/blood-2006-04-017913
84. L. Wang, R. Calcedo, P. Bell, J. Lin, R. L. Grant, D. L. Siegel and J. M. Wilson: Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther, 22(11), 1389-401 (2011) DOI: 10.1089/hum.2011.031
85. D. E. Bowles, S. W. McPhee, C. Li, S. J. Gray, J. J. Samulski, A. S. Camp, J. Li, B. Wang, P. E. Monahan, J. E. Rabinowitz, J. C. Grieger, L. Govindasamy, M. Agbandje- McKenna, X. Xiao and R. J. Samulski: Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther, 20(2), 443-55 (2012) DOI: 10.1038/mt.2011.237
86. M. A. Bartel, J. R. Weinstein and D. V. Schaffer: Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. Gene Ther, 19(6), 694-700 (2012) DOI: 10.1038/gt.2012.20
87. V. Monteilhet, S. Saheb, S. Boutin, C. Leborgne, P. Veron, M. F. Montus, P. Moullier, O. Benveniste and C. Masurier: A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther, 19(11), 2084-91 (2011) DOI: 10.1038/mt.2011.108
88. G. D. Hurlbut, R. J. Ziegler, J. B. Nietupski, J. W. Foley, L. A. Woodworth, E. Meyers, S. D. Bercury, N. N. Pande, D. W. Souza, M. P. Bree, M. J. Lukason, J. Marshall, S. H. Cheng and R. K. Scheule: Preexisting immunity and low expression in primates highlight translational challenges for liverdirected AAV8-mediated gene therapy. Mol Ther, 18(11), 1983-94 (2010) DOI: 10.1038/mt.2010.175
89. J. Mimuro, H. Mizukami, S. Hishikawa, T. Ikemoto, A. Ishiwata, A. Sakata, T. Ohmori, S. Madoiwa, F. Ono, K. Ozawa and Y. Sakata: Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adenoassociated virus 8 vectors. Mol Ther, 21(2), 318-23 (2013) DOI: 10.1038/mt.2012.258
90. F. Mingozzi, Y. Chen, S. C. Edmonson, S. Zhou, R. M. Thurlings, P. P. Tak, K. A. High and M. J. Vervoordeldonk: Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther, 20(4), 417-24 (2013) DOI: 10.1038/gt.2012.55
91. B. F. Hoyer, R. A. Manz, A. Radbruch and F. Hiepe: Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci, 1050, 124-33 (2005) DOI: 10.1196/annals.1313.014
92. F. Mingozzi, Y. Chen, S. L. Murphy, S. C. Edmonson, A. Tai, S. D. Price, M. E. Metzger, S. Zhou, J. F. Wright, R. E. Donahue, C. E. Dunbar and K. A. High: Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol Ther, 20(7), 1410-6 (2012) DOI: 10.1038/mt.2012.84
93. J. H. McIntosh, M. Cochrane, S. Cobbold, H. Waldmann, S. A. Nathwani, A. M. Davidoff and A. C. Nathwani: Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a nondepleting CD4 antibody and cyclosporine. Gene Ther, 19(1), 78-85 (2012) DOI: 10.1038/gt.2011.64
94. F. Mingozzi, X. M. Anguela, G. Pavani, Y. Chen, R. J. Davidson, D. J. Hui, M. Yazicioglu, L. Elkouby, C. J. Hinderer, A. Faella, C. Howard, A. Tai, G. M. Podsakoff, S. Zhou, E. Basner-Tschakarjan, J. F. Wright and K. A. High: Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med, 5(194), 194ra92 (2013)
95. J. F. Wright: AAV Empty Capsids: For Better or for Worse? Mol Ther, 22(1), 1-2 (2014) DOI: 10.1038/mt.2013.268
96. S. Hacein-Bey-Abina, A. Garrigue, G. P. Wang, J. Soulier, A. Lim, E. Morillon, E. Clappier, L. Caccavelli, E. Delabesse, K. Beldjord, V. Asnafi, E. MacIntyre, L. Dal Cortivo, I. Radford, N. Brousse, F. Sigaux, D. Moshous, J. Hauer, A. Borkhardt, B. H. Belohradsky, U. Wintergerst, M. C. Velez, L. Leiva, R. Sorensen, N. Wulffraat, S. Blanche, F. D. Bushman, A. Fischer and M. Cavazzana-Calvo: Insertional oncogenesis in 4 patients after retrovirusmediated gene therapy of SCID-X1. J Clin Invest, 118(9), 3132-42 (2008) DOI: 10.1172/JCI35700
97. L. Xu, C. Gao, M. S. Sands, S. R. Cai, T. C. Nichols, D. A. Bellinger, R. A. Raymer, S. McCorquodale and K. P. Ponder: Neonatal or hepatocyte growth factorpotentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood, 101(10), 3924-32 (2003) DOI: 10.1182/blood-2002-10-3050
98. J. Matrai, M. K. Chuah and T. VandenDriessche: Recent advances in lentiviral vector development and applications. Mol Ther, 18(3), 477-90 (2010) DOI: 10.1038/mt.2009.319
99. L. Naldini, U. Blomer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma and D. Trono: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 272(5259), 263-7 (1996) DOI: 10.1126/science.272.5259.263
100. G. P. Kobinger, D. J. Weiner, Q. C. Yu and J. M. Wilson: Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol, 19(3), 225-30 (2001) DOI: 10.1038/85664
101. D. J. Watson, G. P. Kobinger, M. A. Passini, J. M. Wilson and J. H. Wolfe: Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol Ther, 5(5 Pt 1), 528-37 (2002) DOI: 10.1006/mthe.2002.0584
102. L. F. Wong, M. Azzouz, L. E. Walmsley, Z. Askham, F. J. Wilkes, K. A. Mitrophanous, S. M. Kingsman and N. D. Mazarakis: Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol Ther, 9(1), 101-11 (2004) DOI: 10.1016/j.ymthe.2003.09.017
103. P. L. Sinn, S. L. Sauter and P. B. McCray, Jr.: Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors - design, biosafety, and production. Gene Ther, 12(14), 1089-98 (2005) DOI: 10.1038/sj.gt.3302570
104. C. Baum: Insertional mutagenesis in gene therapy and stem cell biology. Curr Opin Hematol, 14(4), 337-42 (2007) DOI: 10.1097/MOH.0b013e3281900f01
105. H. Miyoshi, U. Blomer, M. Takahashi, F. H. Gage and I. M. Verma: Development of a self-inactivating lentivirus vector. J Virol, 72(10), 8150-7 (1998)
106. K. Cornils, C. Lange, A. Schambach, M. H. Brugman, R. Nowak, M. Lioznov, C. Baum and B. Fehse: Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance. Mol Ther, 17(1), 131-43 (2009) DOI: 10.1038/mt.2008.238
107. E. Montini, D. Cesana, M. Schmidt, F. Sanvito, M. Ponzoni, C. Bartholomae, L. Sergi Sergi, F. Benedicenti, A. Ambrosi, C. Di Serio, C. Doglioni, C. von Kalle and L. Naldini: Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol, 24(6), 687-96 (2006) DOI: 10.1038/nbt1216
108. E. Montini, D. Cesana, M. Schmidt, F. Sanvito, C. C. Bartholomae, M. Ranzani, F. Benedicenti, L. S. Sergi, A. Ambrosi, M. Ponzoni, C. Doglioni, C. Di Serio, C. von Kalle and L. Naldini: The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest, 119(4), 964-75 (2009) DOI: 10.1172/JCI37630
109. L. Biasco, C. Baricordi and A. Aiuti: Retroviral integrations in gene therapy trials. Mol Ther, 20(4), 709-16 (2012) DOI: 10.1038/mt.2011.289
110. H. Chen, H. Yao, L. Huang, Q. Shen, W. Jia and J. Xue: Expression of human factor IX gene in murine plasma through lentiviral vector-infected haematopoietic stem cells. Clin Exp Pharmacol Physiol, 33(12), 1196-201 (2006) DOI: 10.1111/j.1440-1681.2006.04511.x
111. B. W. Bigger, E. K. Siapati, A. Mistry, S. N. Waddington, M. S. Nivsarkar, L. Jacobs, R. Perrett, M. V. Holder, C. Ridler, G. Kemball-Cook, R. R. Ali, S. J. Forbes, C. Coutelle, N. Wright, M. Alison, A. J. Thrasher, D. Bonnet and M. Themis: Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Gene Ther, 13(2), 117-26 (2006) DOI: 10.1038/sj.gt.3302638
112. A. H. Chang, M. T. Stephan and M. Sadelain: Stem cell-derived erythroid cells mediate long-term systemic protein delivery. Nat Biotechnol, 24(8), 1017-21 (2006) DOI: 10.1038/nbt1227
113. A. H. Chang, M. T. Stephan, L. Lisowski and M. Sadelain: Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice. Mol Ther, 16(10), 1745-52 (2008) DOI: 10.1038/mt.2008.161
114. J. E. Bowman, J. S. Reese, K. T. Lingas and S. L. Gerson: Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients. Mol Ther, 8(1), 42-50 (2003) DOI: 10.1016/S1525-0016(03)00141-2
115. M. Sadelain, A. Chang and L. Lisowski: Supplying clotting factors from hematopoietic stem cell-derived erythroid and megakaryocytic lineage cells. Mol Ther, 17(12), 1994-9 (2009) DOI: 10.1038/mt.2009.238
116. G. Zhang, Q. Shi, S. A. Fahs, E. L. Kuether, C. E. Walsh and R. R. Montgomery: Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice. Blood, 116(8), 1235-43 (2010) DOI: 10.1182/blood-2009-11-255612
117. Y. Chen, J. A. Schroeder, E. L. Kuether, G. Zhang and Q. Shi: Platelet Gene Therapy by Lentiviral Gene Delivery to Hematopoietic Stem Cells Restores Hemostasis and Induces Humoral Immune Tolerance in FIX(null) Mice. Mol Ther, 22(1), 169-77 (2014) DOI: 10.1038/mt.2013.197
118. N. Watanabe, K. Ohashi, K. Tatsumi, R. Utoh, I. K. Shim, K. Kanegae, Y. Kashiwakura, T. Ohmori, Y. Sakata, M. Inoue, M. Hasegawa and T. Okano: Genetically modified adipose tissuederived stem/stromal cells, using simian immunodeficiency virus-based lentiviral vectors, in the treatment of hemophilia B. Hum Gene Ther, 24(3), 283-94 (2013) DOI: 10.1089/hum.2012.162
119. D. L. Coutu, J. Cuerquis, R. El Ayoubi, K. A. Forner, R. Roy, M. Francois, M. Griffith, D. Lillicrap, A. M. Yousefi, M. D. Blostein and J. Galipeau: Hierarchical scaffold design for mesenchymal stem cell-based gene therapy of hemophilia B. Biomaterials, 32(1), 295-305 (2011) DOI: 10.1016/j.biomaterials.2010.08.094
120. B. Sayyar, M. Dodd, J. Wen, S. Ma, L. Marquez-Curtis, A. Janowska-Wieczorek and G. Hortelano: Encapsulation of factor IX-engineered mesenchymal stem cells in fibrinogen-alginate microcapsules enhances their viability and transgene secretion. J Tissue Eng, 3(1), 2041731412462018 (2012) DOI: 10.1177/2041731412462018
121. B. Sayyar, M. Dodd, L. Marquez-Curtis, A. Janowska-Wieczorek and G. Hortelano: Cell-matrix Interactions of Factor IX (FIX)- engineered human mesenchymal stromal cells encapsulated in RGD-alginate vs. fibrinogen-alginate microcapsules. Artif Cells Nanomed Biotechnol, 42(2), 102-9 (2014) DOI: 10.3109/21691401.2013.794354
122. B. Sayyar, M. Dodd, L. Marquez-Curtis, A. Janowska-Wieczorek and G. Hortelano: Fibronectin-Alginate microcapsules improve cell viability and protein secretion of encapsulated Factor IX-engineered human mesenchymal stromal cells. Artif Cells Nanomed Biotechnol (2014)
123. S. N. Waddington, M. S. Nivsarkar, A. R. Mistry, S. M. Buckley, G. Kemball-Cook, K. L. Mosley, K. Mitrophanous, P. Radcliffe, M. V. Holder, M. Brittan, A. Georgiadis, F. Al-Allaf, B. W. Bigger, L. G. Gregory, H. T. Cook, R. R. Ali, A. Thrasher, E. G. Tuddenham, M. Themis and C. Coutelle: Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood, 104(9), 2714-21 (2004) DOI: 10.1182/blood-2004-02-0627
124. X. G. Chen, H. Z. Zhu, J. L. Gong, F. Li and J. L. Xue: Efficient delivery of human clotting factor IX after injection of lentiviral vectors in utero. Acta Pharmacol Sin, 25(6), 789-93 (2004)
125. M. K. Chuah, N. Nair and T. VandenDriessche: Recent progress in gene therapy for hemophilia. Hum Gene Ther, 23(6), 557-65 (2012) DOI: 10.1089/hum.2012.088
126. F. Park, K. Ohashi and M. A. Kay: Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood, 96(3), 1173-6 (2000)
127. F. Park and M. A. Kay: Modified HIV-1 based lentiviral vectors have an effect on viral transduction efficiency and gene expression in vitro and in vivo. Mol Ther, 4(3), 164-73 (2001) DOI: 10.1006/mthe.2001.0450
128. L. V. Tsui, M. Kelly, N. Zayek, V. Rojas, K. Ho, Y. Ge, M. Moskalenko, J. Mondesire, J. Davis, M. V. Roey, T. Dull and J. G. McArthur: Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector. Nat Biotechnol, 20(1), 53-7 (2002) DOI: 10.1038/nbt0102-53
129. A. Follenzi, G. Sabatino, A. Lombardo, C. Boccaccio and L. Naldini: Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther, 13(2), 243-60 (2002) DOI: 10.1089/10430340252769770
130. E. Vigna, M. Amendola, F. Benedicenti, A. D. Simmons, A. Follenzi and L. Naldini: Efficient Tet-dependent expression of human factor IX in vivo by a new selfregulating lentiviral vector. Mol Ther, 11(5), 763-75 (2005) DOI: 10.1016/j.ymthe.2004.11.017
131. T. VandenDriessche, L. Thorrez, L. Naldini, A. Follenzi, L. Moons, Z. Berneman, D. Collen and M. K. Chuah: Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigenpresenting cells in vivo. Blood, 100(3), 813-22 (2002) DOI: 10.1182/blood.V100.3.813
132. A. Follenzi, M. Battaglia, A. Lombardo, A. Annoni, M. G. Roncarolo and L. Naldini: Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes longterm expression of human antihemophilic factor IX in mice. Blood, 103(10), 3700-9 (2004) DOI: 10.1182/blood-2003-09-3217
133. B. D. Brown, A. Cantore, A. Annoni, L. S. Sergi, A. Lombardo, P. Della Valle, A. D'Angelo and L. Naldini: A microRNAregulated lentiviral vector mediates stable correction of hemophilia B mice. Blood, 110(13), 4144-52 (2007) DOI: 10.1182/blood-2007-03-078493
134. A. Annoni, B. D. Brown, A. Cantore, L. S. Sergi, L. Naldini and M. G. Roncarolo: In vivo delivery of a microRNAregulated transgene induces antigenspecific regulatory T cells and promotes immunologic tolerance. Blood, 114(25), 5152-61 (2009) DOI: 10.1182/blood-2009-04-214569
135. A. Annoni, A. Cantore, P. Della Valle, K. Goudy, M. Akbarpour, F. Russo, S. Bartolaccini, A. D'Angelo, M. G. Roncarolo and L. Naldini: Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice. EMBO Mol Med, 5(11), 1684-97 (2013) DOI: 10.1002/emmm.201302857
136. T. Kawai and S. Akira: Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity, 34(5), 637-50 (2011) DOI: 10.1016/j.immuni.2011.05.006
137. A. S. Beignon, K. McKenna, M. Skoberne, O. Manches, I. DaSilva, D. G. Kavanagh, M. Larsson, R. J. Gorelick, J. D. Lifson and N. Bhardwaj: Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest, 115(11), 3265-75 (2005) DOI: 10.1172/JCI26032
138. L. Sun, J. Wu, F. Du, X. Chen and Z. J. Chen: Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science, 339(6121), 786-91 (2013) DOI: 10.1126/science.1232458
139. J. Wu, L. Sun, X. Chen, F. Du, H. Shi, C. Chen and Z. J. Chen: Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science, 339(6121), 826-30 (2013) DOI: 10.1126/science.1229963
140. A. Ablasser, M. Goldeck, T. Cavlar, T. Deimling, G. Witte, I. Rohl, K. P. Hopfner, J. Ludwig and V. Hornung: cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING. Nature, 498(7454), 380-4 (2013) DOI: 10.1038/nature12306
141. F. Civril, T. Deimling, C. C. de Oliveira Mann, A. Ablasser, M. Moldt, G. Witte, V. Hornung and K. P. Hopfner: Structural mechanism of cytosolic DNA sensing by cGAS. Nature, 498(7454), 332-7 (2013) DOI: 10.1038/nature12305
142. X. D. Li, J. Wu, D. Gao, H. Wang, L. Sun and Z. J. Chen: Pivotal roles of cGAScGAMP signaling in antiviral defense and immune adjuvant effects. Science, 341(6152), 1390-4 (2013) DOI: 10.1126/science.1244040
143. D. Gao, J. Wu, Y. T. Wu, F. Du, C. Aroh, N. Yan, L. Sun and Z. J. Chen: Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science, 341(6148), 903-6 (2013) DOI: 10.1126/science.1240933
144. A. Schambach, D. Zychlinski, B. Ehrnstroem and C. Baum: Biosafety features of lentiviral vectors. Hum Gene Ther, 24(2), 132-42 (2013) DOI: 10.1089/hum.2012.229
145. A. D. Leavitt, G. Robles, N. Alesandro and H. E. Varmus: Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection. J Virol, 70(2), 721-8 (1996)
146. J. Vargas, Jr., G. L. Gusella, V. Najfeld, M. E. Klotman and A. Cara: Novel integrasedefective lentiviral episomal vectors for gene transfer. Hum Gene Ther, 15(4), 361-72 (2004) DOI: 10.1089/104303404322959515
147. D. T. Saenz, N. Loewen, M. Peretz, T. Whitwam, R. Barraza, K. G. Howell, J. M. Holmes, M. Good and E. M. Poeschla: Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants. J Virol, 78(6), 2906-20 (2004) DOI: 10.1128/JVI.78.6.2906-2920.2004
148. N. H. Staunstrup and J. G. Mikkelsen: Integrase-defective lentiviral vectors - a stage for nonviral integration machineries. Curr Gene Ther, 11(5), 350-62 (2011) DOI: 10.2174/156652311797415881
149. S. J. Nightingale, R. P. Hollis, K. A. Pepper, D. Petersen, X. J. Yu, C. Yang, I. Bahner and D. B. Kohn: Transient gene expression by nonintegrating lentiviral vectors. Mol Ther, 13(6), 1121-32 (2006) DOI: 10.1016/j.ymthe.2006.01.008
150. R. J. Yanez-Munoz, K. S. Balaggan, A. MacNeil, S. J. Howe, M. Schmidt, A. J. Smith, P. Buch, R. E. MacLaren, P. N. Anderson, S. E. Barker, Y. Duran, C. Bartholomae, C. von Kalle, J. R. Heckenlively, C. Kinnon, R. R. Ali and A. J. Thrasher: Effective gene therapy with nonintegrating lentiviral vectors. Nat Med, 12(3), 348-53 (2006) DOI: 10.1038/nm1365
151. S. Philippe, C. Sarkis, M. Barkats, H. Mammeri, C. Ladroue, C. Petit, J. Mallet and C. Serguera: Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci U S A, 103(47), 17684-9 (2006) DOI: 10.1073/pnas.0606197103
152. J. Matrai, A. Cantore, C. C. Bartholomae, A. Annoni, W. Wang, A. Acosta-Sanchez, E. Samara-Kuko, L. De Waele, L. Ma, P. Genovese, M. Damo, A. Arens, K. Goudy, T. C. Nichols, C. von Kalle, L. C. MK, M. G. Roncarolo, M. Schmidt, T. Vandendriessche and L. Naldini: Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology, 53(5), 1696-707 (2011) DOI: 10.1002/hep.24230
153. K. L. Douglas: Toward development of artificial viruses for gene therapy: a comparative evaluation of viral and nonviral transfection. Biotechnol Prog, 24(4), 871-83 (2008)
154. M. Jafari, M. Soltani, S. Naahidi, D. N. Karunaratne and P. Chen: Nonviral approach for targeted nucleic acid delivery. Curr Med Chem, 19(2), 197-208 (2012) DOI: 10.2174/092986712803414141
155. F. Liu, Y. Song and D. Liu: Hydrodynamicsbased transfection in animals by systemic administration of plasmid DNA. Gene Ther, 6(7), 1258-66 (1999) DOI: 10.1038/sj.gt.3300947
156. G. Zhang, Y. K. Song and D. Liu: Longterm expression of human alpha1- antitrypsin gene in mouse liver achieved by intravenous administration of plasmid DNA using a hydrodynamics-based procedure. Gene Ther, 7(15), 1344-9 (2000) DOI: 10.1038/sj.gt.3301229
157. C. H. Miao, A. R. Thompson, K. Loeb and X. Ye: Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther, 3(6), 947-57 (2001) DOI: 10.1006/mthe.2001.0333
158. G. J. Sawyer, M. Rela, M. Davenport, M. Whitehorne, X. Zhang and J. W. Fabre: Hydrodynamic gene delivery to the liver: theoretical and practical issues for clinical application. Curr Gene Ther, 9(2), 128-35 (2009) DOI: 10.2174/156652309787909535
159. S. J. Eastman, K. M. Baskin, B. L. Hodges, Q. Chu, A. Gates, R. Dreusicke, S. Anderson and R. K. Scheule: Development of catheter-based procedures for transducing the isolated rabbit liver with plasmid DNA. Hum Gene Ther, 13(17), 2065-77 (2002) DOI: 10.1089/10430340260395910
160. H. Yoshino, K. Hashizume and E. Kobayashi: Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume. Gene Ther, 13(24), 1696-702 (2006) DOI: 10.1038/sj.gt.3302833
161. K. Kamimura, T. Suda, W. Xu, G. Zhang and D. Liu: Image-guided, lobe-specific hydrodynamic gene delivery to swine liver. Mol Ther, 17(3), 491-9 (2009) DOI: 10.1038/mt.2008.294
162. J. W. Fabre, A. Grehan, M. Whitehorne, G. J. Sawyer, X. Dong, S. Salehi, L. Eckley, X. Zhang, M. Seddon, A. M. Shah, M. Davenport and M. Rela: Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava. Gene Ther, 15(6), 452-62 (2008) DOI: 10.1038/sj.gt.3303079
163. P. B. Hackett, Jr., E. L. Aronovich, D. Hunter, M. Urness, J. B. Bell, S. J. Kass, L. J. Cooper and S. McIvor: Efficacy and safety of Sleeping Beauty transposonmediated gene transfer in preclinical animal studies. Curr Gene Ther, 11(5), 341-9 (2011) DOI: 10.2174/156652311797415827
164. T. VandenDriessche, Z. Ivics, Z. Izsvak and M. K. Chuah: Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood, 114(8), 1461-8 (2009) DOI: 10.1182/blood-2009-04-210427
165. M. J. Fraser, T. Ciszczon, T. Elick and C. Bauser: Precise excision of TTAA-specific lepidopteran transposons piggyBac (IFP2) and tagalong (TFP3) from the baculovirus genome in cell lines from two species of Lepidoptera. Insect Mol Biol, 5(2), 141-51 (1996) DOI: 10.1111/j.1365-2583.1996.tb00048.x
166. S. Ding, X. Wu, G. Li, M. Han, Y. Zhuang and T. Xu: Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell, 122(3), 473-83 (2005) DOI: 10.1016/j.cell.2005.07.013
167. Z. Ivics, P. B. Hackett, R. H. Plasterk and Z. Izsvak: Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell, 91(4), 501-10 (1997) DOI: 10.1016/S0092-8674(00)80436-5
168. Z. Izsvak, Z. Ivics and R. H. Plasterk: Sleeping Beauty, a wide hostrange transposon vector for genetic transformation in vertebrates. J Mol Biol, 302(1), 93-102 (2000) DOI: 10.1006/jmbi.2000.4047
169. L. Mates, M. K. Chuah, E. Belay, B. Jerchow, N. Manoj, A. Acosta-Sanchez, D. P. Grzela, A. Schmitt, K. Becker, J. Matrai, L. Ma, E. Samara-Kuko, C. Gysemans, D. Pryputniewicz, C. Miskey, B. Fletcher, T. VandenDriessche, Z. Ivics and Z. Izsvak: Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet, 41(6), 753-61 (2009) DOI: 10.1038/ng.343
170. E. L. Aronovich, R. S. McIvor and P. B. Hackett: The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet, 20(R1), R14-20 (2011) DOI: 10.1093/hmg/ddr140
171. S. C. Y. Wu, Y. J. J. Meir, C. J. Coates, A. M. Handler, P. Pelczar, S. Moisyadi and J. M. Kaminski: piggyBac is a flexible and highly active transposon as compared to Sleeping Beauty, Tol2 and Mos1 in mammalian cells. Proc Natl Acad Sci U S A, 103(41), 15008-15013 (2006) DOI: 10.1073/pnas.0606979103
172. X. Xue, X. Huang, S. E. Nodland, L. Mates, L. Ma, Z. Izsvak, Z. Ivics, T. W. LeBien, R. S. McIvor, J. E. Wagner and X. Zhou: Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood, 114(7), 1319-30 (2009) DOI: 10.1182/blood-2009-03-210005
173. T. J. Vigdal, C. D. Kaufman, Z. Izsvak, D. F. Voytas and Z. Ivics: Common physical properties of DNA affecting target site selection of sleeping beauty and other Tc1/mariner transposable elements. J Mol Biol, 323(3), 441-52 (2002) DOI: 10.1016/S0022-2836(02)00991-9
174. S. R. Yant, X. Wu, Y. Huang, B. Garrison, S. M. Burgess and M. A. Kay: Highresolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol, 25(6), 2085-94 (2005) DOI: 10.1128/MCB.25.6.2085-2094.2005
175. M. H. Wilson, C. J. Coates and A. L. George, Jr.: PiggyBac transposonmediated gene transfer in human cells. Mol Ther, 15(1), 139-45 (2007) DOI: 10.1038/sj.mt.6300028
176. N. H. Staunstrup, B. Moldt, L. Mates, P. Villesen, M. Jakobsen, Z. Ivics, Z. Izsvak and J. G. Mikkelsen: Hybrid lentivirustransposon vectors with a random integration profile in human cells. Mol Ther, 17(7), 1205-14 (2009) DOI: 10.1038/mt.2009.10
177. O. Walisko, A. Schorn, F. Rolfs, A. Devaraj, C. Miskey, Z. Izsvak and Z. Ivics: Transcriptional activities of the Sleeping Beauty transposon and shielding its genetic cargo with insulators. Mol Ther, 16(2), 359-69 (2008) DOI: 10.1038/sj.mt.6300366
178. S. R. Yant, L. Meuse, W. Chiu, Z. Ivics, Z. Izsvak and M. A. Kay: Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet, 25(1), 35-41 (2000) DOI: 10.1038/75568
179. A. Keravala, C. L. Chavez, G. Hu, L. E. Woodard, P. E. Monahan and M. P. Calos: Long-term phenotypic correction in factor IX knockout mice by using PhiC31 integrase-mediated gene therapy. Gene Ther, 18(8), 842-8 (2011) DOI: 10.1038/gt.2011.31
180. H. M. Thorpe and M. C. Smith: In vitro site-specific integration of bacteriophage DNA catalyzed by a recombinase of the resolvase/invertase family. Proc Natl Acad Sci U S A, 95(10), 5505-10 (1998) DOI: 10.1073/pnas.95.10.5505
181. C. L. Chavez and M. P. Calos: Therapeutic applications of the PhiC31 integrase system. Curr Gene Ther, 11(5), 375-81 (2011) DOI: 10.2174/156652311797415818
182. S. R. Yant, A. Ehrhardt, J. G. Mikkelsen, L. Meuse, T. Pham and M. A. Kay: Transposition from a gutless adenotransposon vector stabilizes transgene expression in vivo. Nat Biotechnol, 20(10), 999-1005 (2002) DOI: 10.1038/nbt738
183. M. A. Hausl, W. Zhang, N. Muther, C. Rauschhuber, H. G. Franck, E. P. Merricks, T. C. Nichols, M. A. Kay and A. Ehrhardt: Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B. Mol Ther, 18(11), 1896-906 (2010) DOI: 10.1038/mt.2010.169
184. M. Hausl, W. Zhang, R. Voigtlander, N. Muther, C. Rauschhuber and A. Ehrhardt: Development of adenovirus hybrid vectors for Sleeping Beauty transposition in large mammals. Curr Gene Ther, 11(5), 363-74 (2011) DOI: 10.2174/156652311797415890
185. Z. Ivics, A. Katzer, E. E. Stuwe, D. Fiedler, S. Knespel and Z. Izsvak: Targeted Sleeping Beauty transposition in human cells. Mol Ther, 15(6), 1137-44 (2007)
186. T. Gaj, C. A. Gersbach and C. F. Barbas, 3rd: ZFN, TALEN, and CRISPR/Casbased methods for genome engineering. Trends Biotechnol, 31(7), 397-405 (2013) DOI: 10.1016/j.tibtech.2013.04.004
187. Q. Liu, D. J. Segal, J. B. Ghiara and C. F. Barbas, 3rd: Design of polydactyl zincfinger proteins for unique addressing within complex genomes. Proc Natl Acad Sci U S A, 94(11), 5525-30 (1997) DOI: 10.1073/pnas.94.11.5525
188. R. R. Beerli, D. J. Segal, B. Dreier and C. F. Barbas, 3rd: Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc Natl Acad Sci U S A, 95(25), 14628-33 (1998) DOI: 10.1073/pnas.95.25.14628
189. R. R. Beerli, B. Dreier and C. F. Barbas, 3rd: Positive and negative regulation of endogenous genes by designed transcription factors. Proc Natl Acad Sci U S A, 97(4), 1495-500 (2000) DOI: 10.1073/pnas.040552697
190. J. Boch, H. Scholze, S. Schornack, A. Landgraf, S. Hahn, S. Kay, T. Lahaye, A. Nickstadt and U. Bonas: Breaking the code of DNA binding specificity of TALtype III effectors. Science, 326(5959), 1509-12 (2009) DOI: 10.1126/science.1178811
191. M. J. Moscou and A. J. Bogdanove: A simple cipher governs DNA recognition by TAL effectors. Science, 326(5959), 1501 (2009) DOI: 10.1126/science.1178817
192. B. Wiedenheft, S. H. Sternberg and J. A. Doudna: RNA-guided genetic silencing systems in bacteria and archaea. Nature, 482(7385), 331-8 (2012) DOI: 10.1038/nature10886
193. M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna and E. Charpentier: A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816-21 (2012) DOI: 10.1126/science.1225829
194. M. Jinek, A. East, A. Cheng, S. Lin, E. Ma and J. Doudna: RNA-programmed genome editing in human cells. Elife, 2, e00471 (2013) DOI: 10.7554/eLife.00471
195. S. W. Cho, S. Kim, J. M. Kim and J. S. Kim: Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol, 31(3), 230-2 (2013) DOI: 10.1038/nbt.2507
196. L. Cong, F. A. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, P. D. Hsu, X. Wu, W. Jiang, L. A. Marraffini and F. Zhang: Multiplex genome engineering using CRISPR/Cas systems. Science, 339(6121), 819-23 (2013) DOI: 10.1126/science.1231143
197. P. Mali, L. Yang, K. M. Esvelt, J. Aach, M. Guell, J. E. DiCarlo, J. E. Norville and G. M. Church: RNA-guided human genome engineering via Cas9. Science, 339(6121), 823-6 (2013) DOI: 10.1126/science.1232033
198. F. D. Urnov, J. C. Miller, Y. L. Lee, C. M. Beausejour, J. M. Rock, S. Augustus, A. C. Jamieson, M. H. Porteus, P. D. Gregory and M. C. Holmes: Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature, 435(7042), 646-51 (2005) DOI: 10.1038/nature03556
199. K. Yusa, S. T. Rashid, H. Strick-Marchand, I. Varela, P. Q. Liu, D. E. Paschon, E. Miranda, A. Ordonez, N. R. Hannan, F. J. Rouhani, S. Darche, G. Alexander, S. J. Marciniak, N. Fusaki, M. Hasegawa, M. C. Holmes, J. P. Di Santo, D. A. Lomas, A. Bradley and L. Vallier: Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells. Nature, 478(7369), 391-4 (2011) DOI: 10.1038/nature10424
200. J. Zou, P. Mali, X. Huang, S. N. Dowey and L. Cheng: Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood, 118(17), 4599-608 (2011) DOI: 10.1182/blood-2011-02-335554
201. H. Li, V. Haurigot, Y. Doyon, T. Li, S. Y. Wong, A. S. Bhagwat, N. Malani, X. M. Anguela, R. Sharma, L. Ivanciu, S. L. Murphy, J. D. Finn, F. R. Khazi, S. Zhou, D. E. Paschon, E. J. Rebar, F. D. Bushman, P. D. Gregory, M. C. Holmes and K. A. High: In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature, 475(7355), 217-21 (2011) DOI: 10.1038/nature10177
202. D. Branzei and M. Foiani: Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol, 9(4), 297-308 (2008) DOI: 10.1038/nrm2351
203. M. E. Moynahan and M. Jasin: Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol, 11(3), 196-207 (2010) DOI: 10.1038/nrm2851
204. X. M. Anguela, R. Sharma, Y. Doyon, J. C. Miller, H. Li, V. Haurigot, M. E. Rohde, S. Y. Wong, R. J. Davidson, S. Zhou, P. D. Gregory, M. C. Holmes and K. A. High: Robust ZFN-mediated genome editing in adult hemophilic mice. Blood, 122(19), 3283-7 (2013) DOI: 10.1182/blood-2013-04-497354
205. S. Rothman, H. Tseng and I. Goldfine: Oral gene therapy: a novel method for the manufacture and delivery of protein drugs. Diabetes Technol Ther, 7(3), 549-57 (2005) DOI: 10.1089/dia.2005.7.549
206. P. Quade-Lyssy, P. Milanov, D. Abriss, C. Ungerer, C. Konigs, E. Seifried and J. Schuttrumpf: Oral gene therapy for hemophilia B using chitosan formulated FIX muteins. J Thromb Haemost (2014) DOI: 10.1111/jth.12572
207. D. Verma, B. Moghimi, P. A. LoDuca, H. D. Singh, B. E. Hoffman, R. W. Herzog and H. Daniell: Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc Natl Acad Sci U S A, 107(15), 7101-6 (2010) DOI: 10.1073/pnas.0912181107
208. X. Wang, A. Sherman, G. Liao, K. W. Leong, H. Daniell, C. Terhorst and R. W. Herzog: Mechanism of oral tolerance induction to therapeutic proteins. Adv Drug Deliv Rev, 65(6), 759-73 (2013) DOI: 10.1016/j.addr.2012.10.013
209. R. Hershberg and D. A. Petrov: Selection on codon bias. Annu Rev Genet, 42, 287-99 (2008) DOI: 10.1146/annurev.genet.42.110807.091442
210. C. R. Ill and H. C. Chiou: Gene therapy progress and prospects: recent progress in transgene and RNAi expression cassettes. Gene Ther, 12(10), 795-802 (2005) DOI: 10.1038/sj.gt.3302524
211. C. N. Lin, C. Y. Kao, C. H. Miao, N. Hamaguchi, H. L. Wu, G. Y. Shi, Y. L. Liu, K. A. High and S. W. Lin: Generation of a novel factor IX with augmented clotting activities in vitro and in vivo. J Thromb Haemost, 8(8), 1773-83 (2010) DOI: 10.1111/j.1538-7836.2010.03913.x
212. C. Y. Kao, C. N. Lin, I. S. Yu, M. H. Tao, H. L. Wu, G. Y. Shi, Y. L. Yang, J. T. Kao and S. W. Lin: FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis. Thromb Haemost, 104(2), 355-65 (2010) DOI: 10.1160/TH09-11-0792
213. P. Simioni, D. Tormene, G. Tognin, S. Gavasso, C. Bulato, N. P. Iacobelli, J. D. Finn, L. Spiezia, C. Radu and V. R. Arruda: X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med, 361(17), 1671-5 (2009) DOI: 10.1056/NEJMoa0904377
214. A. Cantore, N. Nair, P. Della Valle, M. Di Matteo, J. Matrai, F. Sanvito, C. Brombin, C. Di Serio, A. D'Angelo, M. Chuah, L. Naldini and T. Vandendriessche: Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood, 120(23), 4517-20 (2012) DOI: 10.1182/blood-2012-05-432591
215. T. Suwanmanee, G. Hu, T. Gui, C. C. Bartholomae, I. Kutschera, C. von Kalle, M. Schmidt, P. E. Monahan and T. Kafri: Integration-deficient Lentiviral Vectors Expressing Codon-optimized R338L Human FIX Restore Normal Hemostasis in Hemophilia B Mice. Mol Ther (2013)
216. C. Y. Kao, S. J. Yang, M. H. Tao, Y. M. Jeng, I. S. Yu and S. W. Lin: Incorporation of the factor IX Padua mutation into FIXTriple improves clotting activity in vitro and in vivo. Thromb Haemost, 110(2), 244-56 (2013) DOI: 10.1160/TH13-02-0154
217. P. J. Fay: Factor VIII structure and function. Int J Hematol, 83(2), 103-8 (2006) DOI: 10.1532/IJH97.05113
218. C. M. Lynch, D. I. Israel, R. J. Kaufman and A. D. Miller: Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther, 4(3), 259-72 (1993) DOI: 10.1089/hum.1993.4.3-259
219. R. J. Kaufman, L. C. Wasley, M. V. Davies, R. J. Wise, D. I. Israel and A. J. Dorner: Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol, 9(3), 1233-42 (1989)
220. R. C. Hoeben, F. J. Fallaux, S. J. Cramer, D. J. van den Wollenberg, H. van Ormondt, E. Briet and A. J. van der Eb: Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood, 85(9), 2447-54 (1995)
221. S. W. Pipe and R. J. Kaufman: Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins. J Biol Chem, 271(41), 25671-6 (1996) DOI: 10.1074/jbc.271.41.25671
222. A. J. Dorner, D. G. Bole and R. J. Kaufman: The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J Cell Biol, 105(6 Pt 1), 2665-74 (1987) DOI: 10.1083/jcb.105.6.2665
223. A. J. Dorner, L. C. Wasley and R. J. Kaufman: Overexpression of GRP78 mitigates stress induction of glucose regulated proteins and blocks secretion of selective proteins in Chinese hamster ovary cells. EMBO J, 11(4), 1563-71 (1992)
224. L. Tagliavacca, Q. Wang and R. J. Kaufman: ATP-dependent dissociation of non-disulfide-linked aggregates of coagulation factor VIII is a rate-limiting step for secretion. Biochemistry, 39(8), 1973-81 (2000) DOI: 10.1021/bi991896r
225. S. Becker, J. C. Simpson, R. Pepperkok, S. Heinz, C. Herder, M. Grez, E. Seifried and T. Tonn: Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells. Thromb Haemost, 92(1), 23-35 (2004)
226. R. J. Kaufman, L. C. Wasley and A. J. Dorner: Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem, 263(13), 6352-62 (1988)
227. R. R. Montgomery and Q. Shi: Platelet and endothelial expression of clotting factors for the treatment of hemophilia. Thromb Res, 129 Suppl 2, S46-8 (2012) DOI: 10.1016/j.thromres.2012.02.031
228. S. W. Park and S. Y. Choi: Long-term expression of von Willebrand Factor by a VSV-G pseudotyped lentivirus enhances the functional activity of secreted B-Domain-deleted Coagulation Factor VIII. Mol Cells, 24(1), 125-31 (2007)
229. W. L. Nichols, M. B. Hultin, A. H. James, M. J. Manco-Johnson, R. R. Montgomery, T. L. Ortel, M. E. Rick, J. E. Sadler, M. Weinstein and B. P. Yawn: von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia, 14(2), 171-232 (2008) DOI: 10.1111/j.1365-2516.2007.01643.x
230. E. R. Weibel and G. E. Palade: New Cytoplasmic Components in Arterial Endothelia. J Cell Biol, 23, 101-12 (1964) DOI: 10.1083/jcb.23.1.101
231. D. D. Wagner, J. B. Olmsted and V. J. Marder: Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol, 95(1), 355-60 (1982) DOI: 10.1083/jcb.95.1.355
232. W. P. Webster, C. F. Zukoski, P. Hutchin, R. L. Reddick, S. R. Mandel and G. D. Penick: Plasma factor VIII synthesis and control as revealed by canine organ transplantation. Am J Physiol, 220(5), 1147-54 (1971)
233. J. H. Lewis, F. A. Bontempo, J. A. Spero, M. V. Ragni and T. E. Starzl: Liver transplantation in a hemophiliac. N Engl J Med, 312(18), 1189-90 (1985) DOI: 10.1056/NEJM198505023121812
234. F. A. Bontempo, J. H. Lewis, T. J. Gorenc, J. A. Spero, M. V. Ragni, J. P. Scott and T. E. Starzl: Liver transplantation in hemophilia A. Blood, 69(6), 1721-4 (1987)
235. M. G. Zelechowska, J. A. van Mourik and T. Brodniewicz-Proba: Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes. Nature, 317(6039), 729-30 (1985) DOI: 10.1038/317729a0
236. K. L. Wion, D. Kelly, J. A. Summerfield, E. G. Tuddenham and R. M. Lawn: Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature, 317(6039), 726-9 (1985) DOI: 10.1038/317726a0
237. J. Ingerslev, B. S. Christiansen, L. Heickendorff and C. Munck Petersen: Synthesis of factor VIII in human hepatocytes in culture. Thromb Haemost, 60(3), 387-91 (1988)
238. C. Biron-Andreani, C. Bezat-Bouchahda, E. Raulet, L. Pichard-Garcia, J. M. Fabre, J. Saric, J. Baulieux, J. F. Schved and P. Maurel: Secretion of functional plasma haemostasis proteins in long-term primary cultures of human hepatocytes. Br J Haematol, 125(5), 638-46 (2004) DOI: 10.1111/j.1365-2141.2004.04957.x
239. K. Ohashi, J. M. Waugh, M. D. Dake, T. Yokoyama, H. Kuge, Y. Nakajima, M. Yamanouchi, H. Naka, A. Yoshioka and M. A. Kay: Liver tissue engineering at extrahepatic sites in mice as a potential new therapy for genetic liver diseases. Hepatology, 41(1), 132-40 (2005) DOI: 10.1002/hep.20484
240. L. Hellman, B. Smedsrod, H. Sandberg and U. Pettersson: Secretion of coagulant factor VIII activity and antigen by in vitro cultivated rat liver sinusoidal endothelial cells. Br J Haematol, 73(3), 348-55 (1989) DOI: 10.1111/j.1365-2141.1989.tb07751.x
241. H. Do, J. F. Healey, E. K. Waller and P. Lollar: Expression of factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem, 274(28), 19587-92 (1999) DOI: 10.1074/jbc.274.28.19587
242. V. Kumaran, D. Benten, A. Follenzi, B. Joseph, R. Sarkar and S. Gupta: Transplantation of endothelial cells corrects the phenotype in hemophilia A mice. J Thromb Haemost, 3(9), 2022-31 (2005) DOI: 10.1111/j.1538-7836.2005.01508.x
243. A. Follenzi, D. Benten, P. Novikoff, L. Faulkner, S. Raut and S. Gupta: Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin Invest, 118(3), 935-45 (2008)
244. M. E. Fomin, Y. Zhou, A. I. Beyer, J. Publicover, J. L. Baron and M. O. Muench: Production of factor VIII by human liver sinusoidal endothelial cells transplanted in immunodeficient uPA mice. PLoS One, 8(10), e77255 (2013) DOI: 10.1371/journal.pone.0077255
245. T. Shahani, K. Covens, R. Lavend'homme, N. Jazouli, E. Sokal, K. Peerlinck and M. Jacquemin: Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII. J Thromb Haemost, 12(1), 36-42 (2014) DOI: 10.1111/jth.12412
246. M. J. Hollestelle, T. Thinnes, K. Crain, A. Stiko, J. K. Kruijt, T. J. van Berkel, D. J. Loskutoff and J. A. van Mourik: Tissue distribution of factor VIII gene expression in vivo - a closer look. Thromb Haemost, 86(3), 855-61 (2001)
247. C. L. Madeira, M. E. Layman, R. E. de Vera, P. A. Fontes and M. V. Ragni: Extrahepatic factor VIII production in transplant recipient of hemophilia donor liver. Blood, 113(21), 5364-5 (2009) DOI: 10.1182/blood-2009-02-206979
248. M. Jacquemin, A. Neyrinck, M. I. Hermanns, R. Lavend'homme, F. Rega, J. M. Saint-Remy, K. Peerlinck, D. Van Raemdonck and C. J. Kirkpatrick: FVIII production by human lung microvascular endothelial cells. Blood, 108(2), 515-7 (2006) DOI: 10.1182/blood-2005-11-4571
249. M. J. Hollestelle, P. P. Poyck, J. M. Hollestelle, H. A. Marsman, J. A. Mourik and T. M. Gulik: Extra-hepatic factor VIII expression in porcine fulminant hepatic failure. J Thromb Haemost, 3(10), 2274-80 (2005) DOI: 10.1111/j.1538-7836.2005.01543.x
250. J. J. Veltkamp, E. Asfaou, K. van de Torren, J. A. van der Does, N. H. van Tilburg and E. K. Pauwels: Extrahepatic factor VIII synthesis. Lung transplants in hemophilic dogs. Transplantation, 18(1), 56-62 (1974) DOI: 10.1097/00007890-197407000-00009
251. S. A. Fahs, M. T. Hille, Q. Shi, H. Weiler and R. R. Montgomery: A conditional knockout mouse model reveals endothelial cells as the predominant and possibly exclusive source of plasma factor VIII. Blood (2014) DOI: 10.1182/blood-2014-02-555151
252. L. A. Everett, A. C. Cleuren, R. N. Khoriaty and D. Ginsburg: Murine coagulation factor VIII is synthesized in endothelial cells. Blood (2014) DOI: 10.1182/blood-2014-02-554501
253. C. H. Miao, B. R. Harmeling, S. F. Ziegler, B. C. Yen, T. Torgerson, L. Chen, R. J. Yau, B. Peng, A. R. Thompson, H. D. Ochs and D. J. Rawlings: CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice. Blood, 114(19), 4034-44 (2009) DOI: 10.1182/blood-2009-06-228155
254. P. Ye, A. R. Thompson, R. Sarkar, Z. Shen, D. P. Lillicrap, R. J. Kaufman, H. D. Ochs, D. J. Rawlings and C. H. Miao: Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Mol Ther, 10(1), 117-26 (2004) DOI: 10.1016/j.ymthe.2004.04.009
255. B. Peng, P. Ye, B. R. Blazar, G. J. Freeman, D. J. Rawlings, H. D. Ochs and C. H. Miao: Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice. Blood, 112(5), 1662-72 (2008) DOI: 10.1182/blood-2008-01-128413
256. H. Chao, L. Mao, A. T. Bruce and C. E. Walsh: Sustained expression of human factor VIII in mice using a parvovirusbased vector. Blood, 95(5), 1594-9 (2000)
257. B. K. Sack, S. Merchant, D. M. Markusic, A. C. Nathwani, A. M. Davidoff, B. J. Byrne and R. W. Herzog: Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. PLoS One, 7(5), e37671 (2012) DOI: 10.1371/journal.pone.0037671
258. L. Xu, M. Mei, X. Ma and K. P. Ponder: High expression reduces an antibody response after neonatal gene therapy with B domain-deleted human factor VIII in mice. J Thromb Haemost, 5(9), 1805-12 (2007) DOI: 10.1111/j.1538-7836.2007.02629.x
259. H. Matsui, M. Shibata, B. Brown, A. Labelle, C. Hegadorn, C. Andrews, M. Chuah, T. VandenDriessche, C. H. Miao, C. Hough and D. Lillicrap: A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells. Blood, 114(3), 677-85 (2009) DOI: 10.1182/blood-2009-03-202267
260. M. Burton, H. Nakai, P. Colosi, J. Cunningham, R. Mitchell and L. Couto: Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc Natl Acad Sci U S A, 96(22), 12725-30 (1999) DOI: 10.1073/pnas.96.22.12725
261. L. Chen, F. Zhu, J. Li, H. Lu, H. Jiang, R. Sarkar, V. R. Arruda, J. Wang, J. Zhao, G. F. Pierce, Q. Ding, X. Wang, H. Wang, S. W. Pipe, X. Q. Liu, X. Xiao, R. M. Camire and W. Xiao: The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Mol Ther, 15(10), 1856-62 (2007) DOI: 10.1038/sj.mt.6300268
262. C. Mah, R. Sarkar, I. Zolotukhin, M. Schleissing, X. Xiao, H. H. Kazazian and B. J. Byrne: Dual vectors expressing murine factor VIII result in sustained correction of hemophilia A mice. Hum Gene Ther, 14(2), 143-52 (2003) DOI: 10.1089/104303403321070838
263. R. Sarkar, W. Xiao and H. H. Kazazian, Jr.: A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. J Thromb Haemost, 1(2), 220-6 (2003) DOI: 10.1046/j.1538-7836.2003.00096.x
264. D. D. Pittman, E. M. Alderman, K. N. Tomkinson, J. H. Wang, A. R. Giles and R. J. Kaufman: Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood, 81(11), 2925-35 (1993)
265. A. Ishiwata, J. Mimuro, Y. Kashiwakura, M. Niimura, K. Takano, T. Ohmori, S. Madoiwa, H. Mizukami, T. Okada, H. Naka, A. Yoshioka, K. Ozawa and Y. Sakata: Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene. Thromb Res, 118(5), 627-35 (2006) DOI: 10.1016/j.thromres.2005.11.006
266. C. D. Scallan, D. Lillicrap, H. Jiang, X. Qian, S. L. Patarroyo-White, A. E. Parker, T. Liu, J. Vargas, D. Nagy, S. K. Powell, J. F. Wright, P. V. Turner, S. J. Tinlin, S. E. Webster, A. McClelland and L. B. Couto: Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Blood, 102(6), 2031-7 (2003) DOI: 10.1182/blood-2003-01-0292
267. H. Jiang, D. Lillicrap, S. Patarroyo-White, T. Liu, X. Qian, C. D. Scallan, S. Powell, T. Keller, M. McMurray, A. Labelle, D. Nagy, J. A. Vargas, S. Zhou, L. B. Couto and G. F. Pierce: Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood, 108(1), 107-15 (2006) DOI: 10.1182/blood-2005-12-5115
268. D. E. Sabatino, A. M. Lange, E. S. Altynova, R. Sarkar, S. Zhou, E. P. Merricks, H. G. Franck, T. C. Nichols, V. R. Arruda and H. H. Kazazian, Jr.: Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther, 19(3), 442-9 (2011) DOI: 10.1038/mt.2010.240
269. J. D. Finn, M. C. Ozelo, D. E. Sabatino, H. W. Franck, E. P. Merricks, J. M. Crudele, S. Zhou, H. H. Kazazian, D. Lillicrap, T. C. Nichols and V. R. Arruda: Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood, 116(26), 5842-8 (2010) DOI: 10.1182/blood-2010-06-288001
270. K. A. High: The gene therapy journey for hemophilia: are we there yet? Blood (2012) DOI: 10.1182/blood-2012-05-423210
271. H. Lu, L. Chen, J. Wang, B. Huack, R. Sarkar, S. Zhou, R. Xu, Q. Ding, X. Wang, H. Wang and W. Xiao: Complete correction of hemophilia A with adenoassociated viral vectors containing a full-size expression cassette. Hum Gene Ther, 19(6), 648-54 (2008) DOI: 10.1089/hum.2007.0182
272. X. Zhou and N. Muzyczka: In vitro packaging of adeno-associated virus DNA. J Virol, 72(4), 3241-7 (1998)
273. M. Allocca, M. Doria, M. Petrillo, P. Colella, M. Garcia-Hoyos, D. Gibbs, S. R. Kim, A. Maguire, T. S. Rex, U. Di Vicino, L. Cutillo, J. R. Sparrow, D. S. Williams, J. Bennett and A. Auricchio: Serotypedependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest, 118(5), 1955-64 (2008) DOI: 10.1172/JCI34316
274. Z. Wu, H. Yang and P. Colosi: Effect of genome size on AAV vector packaging. Mol Ther, 18(1), 80-6 (2010) DOI: 10.1038/mt.2009.255
275. Y. Lai, Y. Yue and D. Duan: Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2. kb. Mol Ther, 18(1), 75-9 (2010) DOI: 10.1038/mt.2009.256
276. M. L. Hirsch, M. Agbandje-McKenna and R. J. Samulski: Little vector, big gene transduction: fragmented genome reassembly of adeno-associated virus. Mol Ther, 18(1), 6-8 (2010) DOI: 10.1038/mt.2009.280
277. B. Dong, H. Nakai and W. Xiao: Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther, 18(1), 87-92 (2010) DOI: 10.1038/mt.2009.258
278. D. Duan, Y. Yue, Z. Yan, J. Yang and J. F. Engelhardt: Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest, 105(11), 1573-87 (2000) DOI: 10.1172/JCI8317
279. A. M. Douar, K. Poulard, D. Stockholm and O. Danos: Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol, 75(4), 1824-33 (2001) DOI: 10.1128/JVI.75.4.1824-1833.2001
280. P. E. Monahan, C. D. Lothrop, J. Sun, M. L. Hirsch, T. Kafri, B. Kantor, R. Sarkar, D. M. Tillson, J. R. Elia and R. J. Samulski: Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther, 18(11), 1907-16 (2010) DOI: 10.1038/mt.2010.170
281. A. Ishiwata, J. Mimuro, H. Mizukami, Y. Kashiwakura, K. Takano, T. Ohmori, S. Madoiwa, K. Ozawa and Y. Sakata: Liverrestricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice. J Gene Med, 11(11), 1020-9 (2009) DOI: 10.1002/jgm.1391
282. C. Hu and G. S. Lipshutz: AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune responses in mice. Gene Ther, 19(12), 1166-76 (2012) DOI: 10.1038/gt.2011.200
283. N. J. Ward, S. M. Buckley, S. N. Waddington, T. Vandendriessche, M. K. Chuah, A. C. Nathwani, J. McIntosh, E. G. Tuddenham, C. Kinnon, A. J. Thrasher and J. H. McVey: Codon optimization of human factor VIII cDNAs leads to highlevel expression. Blood, 117(3), 798-807 (2011) DOI: 10.1182/blood-2010-05-282707
284. J. McIntosh, P. J. Lenting, C. Rosales, D. Lee, S. Rabbanian, D. Raj, N. Patel, E. G. Tuddenham, O. D. Christophe, J. H. McVey, S. Waddington, A. W. Nienhuis, J. T. Gray, P. Fagone, F. Mingozzi, S. Z. Zhou, K. A. High, M. Cancio, C. Y. Ng, J. Zhou, C. L. Morton, A. M. Davidoff and A. C. Nathwani: Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood, 121(17), 3335-44 (2013) DOI: 10.1182/blood-2012-10-462200
285. T. VandenDriessche, V. Vanslembrouck, I. Goovaerts, H. Zwinnen, M. L. Vanderhaeghen, D. Collen and M. K. Chuah: Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc Natl Acad Sci U S A, 96(18), 10379-84 (1999) DOI: 10.1073/pnas.96.18.10379
286. L. Xu, T. C. Nichols, R. Sarkar, S. McCorquodale, D. A. Bellinger and K. P. Ponder: Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liverdirected neonatal gene therapy. Proc Natl Acad Sci U S A, 102(17), 6080-5 (2005) DOI: 10.1073/pnas.0409249102
287. J. S. Powell, M. V. Ragni, G. C. White, 2nd, J. M. Lusher, C. Hillman-Wiseman, T. E. Moon, V. Cole, S. Ramanathan- Girish, H. Roehl, N. Sajjadi, D. J. Jolly and D. Hurst: Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood, 102(6), 2038-45 (2003) DOI: 10.1182/blood-2003-01-0167
288. J. E. McCormack, W. Edwards, J. Sensintaffer, L. Lillegren, M. Kozloski, D. Brumm, L. Karavodin, D. J. Jolly and J. Greengard: Factors affecting longterm expression of a secreted transgene product after intravenous administration of a retroviral vector. Mol Ther, 3(4), 516-25 (2001) DOI: 10.1006/mthe.2000.0259
289. H. H. Roehl, M. E. Leibbrandt, J. S. Greengard, E. Kamantigue, W. G. Glass, M. Giedlin, K. Boekelheide, D. E. Johnson, D. J. Jolly and N. C. Sajjadi: Analysis of testes and semen from rabbits treated by intravenous injection with a retroviral vector encoding the human factor VIII gene: no evidence of germ line transduction. Hum Gene Ther, 11(18), 2529-40 (2000) DOI: 10.1089/10430340050208000
290. N. A. Kootstra, R. Matsumura and I. M. Verma: Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol Ther, 7(5 Pt 1), 623-31 (2003) DOI: 10.1016/S1525-0016(03)00073-X
291. F. Park: Correction of bleeding diathesis without liver toxicity using arenaviralpseudotyped HIV-1-based vectors in hemophilia A mice. Hum Gene Ther, 14(15), 1489-94 (2003) DOI: 10.1089/104303403769211691
292. K. Ogata, J. Mimuro, J. Kikuchi, T. Tabata, Y. Ueda, M. Naito, S. Madoiwa, K. Takano, M. Hasegawa, K. Ozawa and Y. Sakata: Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for hemophilia A gene therapy. Gene Ther, 11(3), 253-9 (2004) DOI: 10.1038/sj.gt.3302174
293. C. S. Stein, Y. Kang, S. L. Sauter, K. Townsend, P. Staber, T. A. Derksen, I. Martins, J. Qian, B. L. Davidson and P. B. McCray, Jr.: In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. Mol Ther, 3(6), 850-6 (2001) DOI: 10.1006/mthe.2001.0325
294. Y. Kang, L. Xie, D. T. Tran, C. S. Stein, M. Hickey, B. L. Davidson and P. B. McCray, Jr.: Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Blood, 106(5), 1552-8 (2005) DOI: 10.1182/blood-2004-11-4358
295. P. L. Sinn, J. D. Goreham-Voss, A. C. Arias, M. A. Hickey, W. Maury, C. P. Chikkanna-Gowda and P. B. McCray, Jr.: Enhanced gene expression conferred by stepwise modification of a nonprimate lentiviral vector. Hum Gene Ther, 18(12), 1244-52 (2007) DOI: 10.1089/hum.2006.127
296. H. Matsui, C. Hegadorn, M. Ozelo, E. Burnett, A. Tuttle, A. Labelle, P. B. McCray, Jr., L. Naldini, B. Brown, C. Hough and D. Lillicrap: A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A. Mol Ther, 19(4), 723-30 (2011) DOI: 10.1038/mt.2010.290
297. T. Abel, E. El Filali, J. Waern, I. C. Schneider, Q. Yuan, R. C. Munch, M. Hick, G. Warnecke, N. Madrahimov, R. E. Kontermann, J. Schuttrumpf, U. C. Muller, J. Seppen, M. Ott and C. J. Buchholz: Specific gene delivery to liver sinusoidal and artery endothelial cells. Blood, 122(12), 2030-8 (2013) DOI: 10.1182/blood-2012-11-468579
298. T. Vandendriessche and M. K. Chuah: Targeting endothelial cells by gene therapy. Blood, 122(12), 1993-4 (2013) DOI: 10.1182/blood-2013-08-518266
299. R. C. Hoeben, M. P. Einerhand, E. Briet, H. van Ormondt, D. Valerio and A. J. van der Eb: Toward gene therapy in haemophilia A: retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb Haemost, 67(3), 341-5 (1992)
300. G. L. Evans and R. A. Morgan: Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci U S A, 95(10), 5734-9 (1998) DOI: 10.1073/pnas.95.10.5734
301. A. Ramezani and R. G. Hawley: Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector. Blood, 114(3), 526-34 (2009) DOI: 10.1182/blood-2009-01-199653
302. M. Moayeri, A. Ramezani, R. A. Morgan, T. S. Hawley and R. G. Hawley: Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells. Mol Ther, 10(5), 892-902 (2004) DOI: 10.1016/j.ymthe.2004.08.006
303. L. M. Ide, N. N. Iwakoshi, B. Gangadharan, S. Jobe, R. Moot, D. McCarty, C. B. Doering and H. T. Spencer: Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A. J Gene Med, 12(4), 333-44 (2010) DOI: 10.1002/jgm.1442
304. L. M. Ide, B. Gangadharan, K. Y. Chiang, C. B. Doering and H. T. Spencer: Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. Blood, 110(8), 2855-63 (2007) DOI: 10.1182/blood-2007-04-082602
305. A. Van Damme, L. Thorrez, L. Ma, H. Vandenburgh, J. Eyckmans, F. Dell'Accio, C. De Bari, F. Luyten, D. Lillicrap, D. Collen, T. VandenDriessche and M. K. Chuah: Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells. Stem Cells, 24(4), 896-907 (2006) DOI: 10.1634/stemcells.2003-0106
306. A. Tiede, M. Eder, M. von Depka, K. Battmer, S. Luther, H. P. Kiem, A. Ganser and M. Scherr: Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction. Gene Ther, 10(22), 1917-25 (2003) DOI: 10.1038/sj.gt.3302093
307. J. Kikuchi, J. Mimuro, K. Ogata, T. Tabata, Y. Ueda, A. Ishiwata, K. Kimura, K. Takano, S. Madoiwa, H. Mizukami, Y. Hanazono, A. Kume, M. Hasegawa, K. Ozawa and Y. Sakata: Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice. J Gene Med, 6(10), 1049-60 (2004) DOI: 10.1002/jgm.609
308. C. Herder, T. Tonn, R. Oostendorp, S. Becker, U. Keller, C. Peschel, M. Grez and E. Seifried: Sustained expansion and transgene expression of coagulation factor VIII-transduced cord blood-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol, 23(12), 2266-72 (2003) DOI: 10.1161/01.ATV.0000100403.78731.9F
309. A. Ramezani, L. A. Zweier-Renn and R. G. Hawley: Factor VIII delivered by haematopoietic stem cell-derived B cells corrects the phenotype of haemophilia A mice. Thromb Haemost, 105(4), 676-87 (2011) DOI: 10.1160/TH10-11-0725
310. S. Kanaji, S. A. Fahs, Q. Shi, S. L. Haberichter and R. R. Montgomery: Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis. J Thromb Haemost, 10(8), 1646-52 (2012) DOI: 10.1111/j.1538-7836.2012.04797.x
311. H. V. Yarovoi, D. Kufrin, D. E. Eslin, M. A. Thornton, S. L. Haberichter, Q. Shi, H. Zhu, R. Camire, S. S. Fakharzadeh, M. A. Kowalska, D. A. Wilcox, B. S. Sachais, R. R. Montgomery and M. Poncz: Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood, 102(12), 4006-13 (2003) DOI: 10.1182/blood-2003-05-1519
312. Q. Shi, D. A. Wilcox, S. A. Fahs, H. Weiler, C. W. Wells, B. C. Cooley, D. Desai, P. A. Morateck, J. Gorski and R. R. Montgomery: Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest, 116(7), 1974-82 (2006) DOI: 10.1172/JCI28416
313. Q. Shi, D. A. Wilcox, S. A. Fahs, J. Fang, B. D. Johnson, L. M. Du, D. Desai and R. R. Montgomery: Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost, 5(2), 352-61 (2007) DOI: 10.1111/j.1538-7836.2007.02346.x
314. T. Ohmori, J. Mimuro, K. Takano, S. Madoiwa, Y. Kashiwakura, A. Ishiwata, M. Niimura, K. Mitomo, T. Tabata, M. Hasegawa, K. Ozawa and Y. Sakata: Efficient expression of a transgene in platelets using simian immunodeficiency virus-based vector harboring glycoprotein Ibalpha promoter: in vivo model for platelet-targeting gene therapy. FASEB J, 20(9), 1522-4 (2006) DOI: 10.1096/fj.05-5161fje
315. L. M. Du, P. Nurden, A. T. Nurden, T. C. Nichols, D. A. Bellinger, E. S. Jensen, S. L. Haberichter, E. Merricks, R. A. Raymer, J. Fang, S. B. Koukouritaki, P. M. Jacobi, T. B. Hawkins, K. Cornetta, Q. Shi and D. A. Wilcox: Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nat Commun, 4, 2773 (2013) DOI: 10.1038/ncomms3773
316. Q. Shi, E. L. Kuether, Y. Chen, J. A. Schroeder, S. A. Fahs and R. R. Montgomery: Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells. Blood, 123(3), 395-403 (2014) DOI: 10.1182/blood-2013-08-520478
317. E. L. Kuether, J. A. Schroeder, S. A. Fahs, B. C. Cooley, Y. Chen, R. R. Montgomery, D. A. Wilcox and Q. Shi: Lentivirusmediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity. J Thromb Haemost, 10(8), 1570-80 (2012) DOI: 10.1111/j.1538-7836.2012.04791.x
318. M. A. Coleman, J. A. Bridge, S. W. Lane, C. M. Dixon, G. R. Hill, J. W. Wells, R. Thomas and R. J. Steptoe: Tolerance induction with gene-modified stem cells and immune-preserving conditioning in primed mice: restricting antigen to differentiated antigen-presenting cells permits efficacy. Blood, 121(6), 1049-58 (2013) DOI: 10.1182/blood-2012-06-434100
319. J. Gewirtz, M. A. Thornton, L. Rauova and M. Poncz: Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors. J Thromb Haemost, 6(7), 1160-6 (2008) DOI: 10.1111/j.1538-7836.2008.02992.x
320. T. K. Greene, C. Wang, J. D. Hirsch, L. Zhai, J. Gewirtz, M. A. Thornton, H. Z. Miao, S. W. Pipe, R. J. Kaufman, R. M. Camire, V. R. Arruda, M. A. Kowalska and M. Poncz: In vivo efficacy of plateletdelivered, high specific activity factor VIII variants. Blood, 116(26), 6114-22 (2010) DOI: 10.1182/blood-2010-06-293308
321. C. B. Doering: Retroviral modification of mesenchymal stem cells for gene therapy of hemophilia. Methods Mol Biol, 433, 203-12 (2008) DOI: 10.1007/978-1-59745-237-3-12
322. A. Van Damme, M. K. Chuah, F. Dell'accio, C. De Bari, F. Luyten, D. Collen and T. VandenDriessche: Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats. Haemophilia, 9(1), 94-103 (2003) DOI: 10.1046/j.1365-2516.2003.00709.x
323. Y. Kashiwakura, T. Ohmori, J. Mimuro, A. Yasumoto, A. Ishiwata, A. Sakata, S. Madoiwa, M. Inoue, M. Hasegawa, K. Ozawa and Y. Sakata: Intra-articular injection of mesenchymal stem cells expressing coagulation factor ameliorates hemophilic arthropathy in factor VIIIdeficient mice. J Thromb Haemost, 10(9), 1802-13 (2012) DOI: 10.1111/j.1538-7836.2012.04851.x
324. C. D. Porada, C. Sanada, C. J. Kuo, E. Colletti, W. Mandeville, J. Hasenau, E. D. Zanjani, R. Moot, C. Doering, H. T. Spencer and G. Almeida-Porada: Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC. Exp Hematol, 39(12), 1124-1135 e4 (2011)
325. H. Matsui, M. Shibata, B. Brown, A. Labelle, C. Hegadorn, C. Andrews, R. P. Hebbel, J. Galipeau, C. Hough and D. Lillicrap: Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells, 25(10), 2660-9 (2007) DOI: 10.1634/stemcells.2006-0699
326. K. Tatsumi, M. Sugimoto, D. Lillicrap, M. Shima, K. Ohashi, T. Okano and H. Matsui: A Novel Cell-Sheet Technology That Achieves Durable Factor VIII Delivery in a Mouse Model of Hemophilia A. PLoS One, 8(12), e83280 (2013) DOI: 10.1371/journal.pone.0083280
327. M. C. Ozelo, B. Vidal, C. Brown, C. Notley, C. Hegadorn, S. Webster, L. Harpell, J. Ahlin, A. Winterborn, J. Handforth, V. R. Arruda, C. Hough and D. Lillicrap: Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response. Blood, 123(26), 4045-53 (2014) DOI: 10.1182/blood-2013-12-545780
328. I. de Lazaro, A. Yilmazer and K. Kostarelos: Induced pluripotent stem (iPS) cells: A new source for cell-based therapeutics? J Control Release, 185C, 37-44 (2014) DOI: 10.1016/j.jconrel.2014.04.011
329. Y. Kashiwakura, T. Ohmori, J. Mimuro, S. Madoiwa, M. Inoue, M. Hasegawa, K. Ozawa and Y. Sakata: Production of functional coagulation factor VIII from iPSCs using a lentiviral vector. Haemophilia, 20(1), e40-4 (2014) DOI: 10.1111/hae.12311
330. C. H. Miao, P. Ye, A. R. Thompson, D. J. Rawlings and H. D. Ochs: Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice. Blood, 108(1), 19-27 (2006) DOI: 10.1182/blood-2005-11-4532
331. B. Peng, P. Ye, D. J. Rawlings, H. D. Ochs and C. H. Miao: Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy. Blood, 114(20), 4373-82 (2009) DOI: 10.1182/blood-2009-05-217315
332. J. Wang, S. G. Mansfield, C. A. Cote, P. D. Jiang, K. Weng, M. J. Amar, B. H. Brewer, Jr., A. T. Remaley, G. J. McGarrity, M. A. Garcia-Blanco and M. Puttaraju: Transsplicing into highly abundant albumin transcripts for production of therapeutic proteins in vivo. Mol Ther, 17(2), 343-51 (2009) DOI: 10.1038/mt.2008.260
333. H. Chao, S. G. Mansfield, R. C. Bartel, S. Hiriyanna, L. G. Mitchell, M. A. Garcia- Blanco and C. E. Walsh: Phenotype correction of hemophilia A mice by spliceosome-mediated RNA transsplicing. Nat Med, 9(8), 1015-9 (2003) DOI: 10.1038/nm900
334. J. R. Ohlfest, J. L. Frandsen, S. Fritz, P. D. Lobitz, S. G. Perkinson, K. J. Clark, G. Nelsestuen, N. S. Key, R. S. McIvor, P. B. Hackett and D. A. Largaespada: Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood, 105(7), 2691-8 (2005) DOI: 10.1182/blood-2004-09-3496
335. L. Liu, C. Mah and B. S. Fletcher: Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelialtargeted sleeping beauty transposon. Mol Ther, 13(5), 1006-15 (2006) DOI: 10.1016/j.ymthe.2005.11.021
336. L. Liu, H. Liu, C. Mah and B. S. Fletcher: Indoleamine 2,3-dioxygenase attenuates inhibitor development in gene-therapytreated hemophilia A mice. Gene Ther, 16(6), 724-33 (2009) DOI: 10.1038/gt.2009.13
337. B. T. Kren, G. M. Unger, L. Sjeklocha, A. A. Trossen, V. Korman, B. M. Diethelm- Okita, M. T. Reding and C. J. Steer: Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest, 119(7), 2086-99 (2009)
338. K. Bowman, R. Sarkar, S. Raut and K. W. Leong: Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles. J Control Release, 132(3), 252-9 (2008) DOI: 10.1016/j.jconrel.2008.06.019
339. S. S. Dhadwar, J. Kiernan, J. Wen and G. Hortelano: Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice. J Thromb Haemost, 8(12), 2743-50 (2010) DOI: 10.1111/j.1538-7836.2010.04116.x
340. D. A. Roth, N. E. Tawa, Jr., J. M. O'Brien, D. A. Treco and R. F. Selden: Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med, 344(23), 1735-42 (2001) DOI: 10.1056/NEJM200106073442301
341. Y. Lin, D. J. Weisdorf, A. Solovey and R. P. Hebbel: Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest, 105(1), 71-7 (2000) DOI: 10.1172/JCI8071
342. Y. Lin, L. Chang, A. Solovey, J. F. Healey, P. Lollar and R. P. Hebbel: Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. Blood, 99(2), 457-62 (2002) DOI: 10.1182/blood.V99.2.457
343. A. Somani, J. Nguyen, L. C. Milbauer, A. Solovey, S. Sajja and R. P. Hebbel: The establishment of murine blood outgrowth endothelial cells and observations relevant to gene therapy. Transl Res, 150(1), 30-9 (2007) DOI: 10.1016/j.trsl.2007.02.002
344. X. Liu, M. Liu, Z. Xue, Q. Pan, L. Wu, Z. Long, K. Xia, D. Liang and J. Xia: Non-viral ex vivo transduction of human hepatocyte cells to express factor VIII using a human ribosomal DNA-targeting vector. J Thromb Haemost, 5(2), 347-51 (2007) DOI: 10.1111/j.1538-7836.2007.02355.x
345. S. Kasuda, A. Kubo, Y. Sakurai, S. Irion, K. Ohashi, K. Tatsumi, Y. Nakajima, Y. Saito, K. Hatake, S. W. Pipe, M. Shima and A. Yoshioka: Establishment of embryonic stem cells secreting human factor VIII for cell-based treatment of hemophilia A. J Thromb Haemost, 6(8), 1352-9 (2008) DOI: 10.1111/j.1538-7836.2008.03022.x
346. D. Xu, Z. Alipio, L. M. Fink, D. M. Adcock, J. Yang, D. C. Ward and Y. Ma: Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci U S A, 106(3), 808-13 (2009) DOI: 10.1073/pnas.0812090106
347. M. Oshimura and M. Katoh: Transfer of human artificial chromosome vectors into stem cells. Reprod Biomed Online, 16(1), 57-69 (2008) DOI: 10.1016/S1472-6483(10)60557-3
348. Y. Kazuki and M. Oshimura: Human artificial chromosomes for gene delivery and the development of animal models. Mol Ther, 19(9), 1591-601 (2011) DOI: 10.1038/mt.2011.136
349. Y. Kazuki, H. Hoshiya, M. Takiguchi, S. Abe, Y. Iida, M. Osaki, M. Katoh, M. Hiratsuka, Y. Shirayoshi, K. Hiramatsu, E. Ueno, N. Kajitani, T. Yoshino, K. Kazuki, C. Ishihara, S. Takehara, S. Tsuji, F. Ejima, A. Toyoda, Y. Sakaki, V. Larionov, N. Kouprina and M. Oshimura: Refined human artificial chromosome vectors for gene therapy and animal transgenesis. Gene Ther, 18(4), 384-93 (2011) DOI: 10.1038/gt.2010.147
350. M. Katoh, F. Ayabe, S. Norikane, T. Okada, H. Masumoto, S. Horike, Y. Shirayoshi and M. Oshimura: Construction of a novel human artificial chromosome vector for gene delivery. Biochem Biophys Res Commun, 321(2), 280-90 (2004) DOI: 10.1016/j.bbrc.2004.06.145
351. Y. Yakura, C. Ishihara, H. Kurosaki, Y. Kazuki, N. Komatsu, Y. Okada, T. Doi, H. Takeya and M. Oshimura: An induced pluripotent stem cell-mediated and integration-free factor VIII expression system. Biochem Biophys Res Commun, 431(2), 336-41 (2013) DOI: 10.1016/j.bbrc.2012.12.096
352. C. B. Doering, J. F. Healey, E. T. Parker, R. T. Barrow and P. Lollar: Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion. J Biol Chem, 279(8), 6546-52 (2004) DOI: 10.1074/jbc.M312451200
353. C. B. Doering, J. F. Healey, E. T. Parker, R. T. Barrow and P. Lollar: High level expression of recombinant porcine coagulation factor VIII. J Biol Chem, 277(41), 38345-9 (2002) DOI: 10.1074/jbc.M206959200
354. H. C. Brown, B. Gangadharan and C. B. Doering: Enhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response. J Biol Chem, 286(27), 24451-7 (2011) DOI: 10.1074/jbc.M111.238758
355. B. Gangadharan, E. T. Parker, L. M. Ide, H. T. Spencer and C. B. Doering: Highlevel expression of porcine factor VIII from genetically modified bone marrowderived stem cells. Blood, 107(10), 3859-64 (2006) DOI: 10.1182/blood-2005-12-4961
356. J. M. Johnston, G. Denning, C. B. Doering and H. T. Spencer: Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A. Gene Ther, 20(6), 607-15 (2013) DOI: 10.1038/gt.2012.76
357. K. L. Dooriss, G. Denning, B. Gangadharan, E. H. Javazon, D. A. McCarty, H. T. Spencer and C. B. Doering: Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A. Hum Gene Ther, 20(5), 465-78 (2009) DOI: 10.1089/hum.2008.150
358. C. B. Doering, G. Denning, K. Dooriss, B. Gangadharan, J. M. Johnston, K. W. Kerstann, D. A. McCarty and H. T. Spencer: Directed engineering of a highexpression chimeric transgene as a strategy for gene therapy of hemophilia A. Mol Ther, 17(7), 1145-54 (2009) DOI: 10.1038/mt.2009.35
359. E. T. Parker, J. F. Healey, R. T. Barrow, H. N. Craddock and P. Lollar: Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood, 104(3), 704-10 (2004) DOI: 10.1182/blood-2003-11-3891
360. C. L. Kempton, T. C. Abshire, R. A. Deveras, W. K. Hoots, J. C. Gill, C. M. Kessler, N. S. Key, B. A. Konkle, P. Kuriakose, D. E. Macfarlane and G. Bergman: Pharmacokinetics and safety of OBI-1, a recombinant B domaindeleted porcine factor VIII, in subjects with haemophilia A. Haemophilia, 18(5), 798-804 (2012) DOI: 10.1111/j.1365-2516.2012.02789.x
361. J. F. Healey, E. T. Parker, R. T. Barrow, T. J. Langley, W. R. Church and P. Lollar: The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice. Thromb Haemost, 102(1), 35-41 (2009)
362. C. B. Doering, B. Gangadharan, H. Z. Dukart and H. T. Spencer: Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity. Mol Ther, 15(6), 1093-9 (2007)
363. D. E. Sabatino, C. F. Freguia, R. Toso, A. Santos, E. P. Merricks, H. H. Kazazian, Jr., T. C. Nichols, R. M. Camire and V. R. Arruda: Recombinant canine B-domaindeleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model. Blood, 114(20), 4562-5 (2009) DOI: 10.1182/blood-2009-05-220327
364. J. I. Siner, N. P. Iacobelli, D. E. Sabatino, L. Ivanciu, S. Zhou, M. Poncz, R. M. Camire and V. R. Arruda: Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. Blood, 121(21), 4396-403 (2013) DOI: 10.1182/blood-2012-10-464164
365. L. Chen, H. Lu, J. Wang, R. Sarkar, X. Yang, H. Wang, K. A. High and W. Xiao: Enhanced factor VIII heavy chain for gene therapy of hemophilia A. Mol Ther, 17(3), 417-24 (2009) DOI: 10.1038/mt.2008.292
366. S. D. Roth, J. Schuttrumpf, P. Milanov, D. Abriss, C. Ungerer, P. Quade-Lyssy, J. C. Simpson, R. Pepperkok, E. Seifried and T. Tonn: Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A. PLoS One, 7(9), e44505 (2012) DOI: 10.1371/journal.pone.0044505
367. P. Margaritis, V. R. Arruda, M. Aljamali, R. M. Camire, A. Schlachterman and K. A. High: Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII. J Clin Invest, 113(7), 1025-31 (2004) DOI: 10.1172/JCI20106
368. T. Ohmori, A. Ishiwata, Y. Kashiwakura, S. Madoiwa, K. Mitomo, H. Suzuki, M. Hasegawa, J. Mimuro and Y. Sakata: Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets. Mol Ther, 16(8), 1359-65 (2008) DOI: 10.1038/mt.2008.117
369. T. Kitazawa, T. Igawa, Z. Sampei, A. Muto, T. Kojima, T. Soeda, K. Yoshihashi, Y. Okuyama-Nishida, H. Saito, H. Tsunoda, T. Suzuki, H. Adachi, T. Miyazaki, S. Ishii, M. Kamata-Sakurai, T. Iida, A. Harada, K. Esaki, M. Funaki, C. Moriyama, E. Tanaka, Y. Kikuchi, T. Wakabayashi, M. Wada, M. Goto, T. Toyoda, A. Ueyama, S. Suzuki, K. Haraya, T. Tachibana, Y. Kawabe, M. Shima, A. Yoshioka and K. Hattori: A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med, 18(10), 1570-4 (2012) DOI: 10.1038/nm.2942
370. P. Milanov, L. Ivanciu, D. Abriss, P. Quade-Lyssy, W. Miesbach, S. Alesci, T. Tonn, M. Grez, E. Seifried and J. Schuttrumpf: Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice. Blood, 119(2), 602-11 (2012) DOI: 10.1182/blood-2011-05-353672